 
 A PHASE II RANDOMIZED AND CONTROLLED INVESTIGATION OF 
SIX WEEKS OF ORAL VALGANCICLOVIR THERAPY IN INFANTS  AND 
CHILDREN  WITH CONGENITAL CYTOMEGALOVIRUS INFECTION 
AND HEARING LOSS 
DMID Protocol Number:  11-0069 
 
DMID Funding Mechanism:  HHSN272201100035C 
Phar maceutical Support Provided by:  [CONTACT_8229], Inc.  
IND Sponsor:  DMID  
Principal Investigator:   [INVESTIGATOR_10086] W. Kimberlin, M.D.  
DMID Clinical Project Manager :  Walla Dempsey, Ph.D. 
DMID Medical Monitor:  Venus Shahama tdar, MD  
Version Number:  4.0 
28 April 2016   
 
 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128241] met 
protocol eligibility criteria.  This trial will be conducted in compliance with the protocol, 
International Conference on Harmonization Good Clinical Practice E6 (ICH -GCP), and 
the applicable regulatory requirements, including:  
• U.S. Code of Federal Regulations applicable to clinical studies (45 CFR 46 and 21 CFR in cluding parts 50 and 56 concerning informed consent and IRB regulations, if 
under IND, 21 CFR 312).  
• Directive 9115071EEC: The Rules Governing Medicinal Products in the European Community.  
• Completion of Human Subjects Protection Training.  Refer to http://grants.nih.gov/grants/guide/notice- files/NOT -OD-01-061.html
; 
http://cme.cancer.g ov/clinicaltrials/learning/humanparticipant -protections.asp   
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128242] this protocol  “A Phase II 
Randomized and Controlled Investigation of Six Weeks of Oral 
Valganciclovir Therapy in Infants a nd Children  with Congenital 
Cytomegalovirus Infection and Hearing Loss ” and attachments  and provide the 
necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable U.S. clinical sites.  It is understood that no deviations from the protocol may be made without permission of the Sponsor.
 
 
Site Investigator:  
 
Signed:   Date:   
 Name  
    
 [CONTACT_114841] #11- 0069, Version 4.[ADDRESS_128243] OF ABBREVIATIONS ......................................................................................................................... VIII 
PROTOCOL SUMMARY  ................................................................................................................................ XI  
1. KEY ROLES  ............................................................................................................................................ 1  
2. BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ...................................................... 7  
2.1. BACKGROUND INFORMATION  ....................................................................................................................... 7  
2.1.1.  Retrospective diagnosis of congenital CMV  ................................................................................. 8  
2.1.2.  Treatment of Congenital CMV  ........................................................................................................ 9  
2.2. RATIONALE  ................................................................................................................................................. 11 
2.3. POTENTIAL RISKS AND BENEFITS  ..............................................................................................................  13 
2.3.1.  Potential Risks ................................................................................................................................. 13 
2.3.2.  Known Potential Benefits  ............................................................................................................... 13 
3. OBJECTIVES ......................................................................................................................................... 14 
3.1. STUDY OBJECTIVES  ................................................................................................................................... 14 
3.2. STUDY OUTCOME MEASURES  ................................................................................................................... 14 
3.2.1.  Primary Outcome Measure  ........................................................................................................... 14 
3.2.2.  Secondary Outcome Measures  .................................................................................................... 14 
3.2.3.  Tertiary Outcome Measures  .......................................................................................................... 15 
4. STUDY DESIGN  ..................................................................................................................................... 16 
4.1. SUBSTUDIES (IF APPLICABLE ) .................................................................................................................... [ADDRESS_128244] EXCLUSION CRITERIA  ................................................................................................................ 18 
5.4. TREATMENT ASSIGNMENT PROCEDURES  ................................................................................................. 19 
5.4.1.  Randomization Procedures  ........................................................................................................... 19 
5.4.2.  Masking Procedures  ....................................................................................................................... 19 
5.4.3.  Reasons for Withdrawal Before Randomization ........................................................................ 20 
5.4.4.  Reasons for Withdrawal After Randomization and During Treatment  .................................... 20 
5.4.5.  Reasons for Withdrawal After Randomization and After Completion of Treatment  .............. 21 
5.4.6.  Handling of Withdrawals  ................................................................................................................ 21 
5.4.7.  Termination of Study  ...................................................................................................................... 22 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 _____________________________________________________________________________________________  
v 6. STUDY INTERVENTION/INVESTIGATIONAL PRODUCT  ................................................................. [ADDRESS_128245] Storage and Stability  ....................................................................................................... 24 
6.2. DOSAGE , PREPARATION AND ADMINISTRATION OF STUDY INTERVENTION /INVESTIGATIONAL PRODUCT
 24 
6.3. MODIFICATION OF STUDY INTERVENTION /INVESTIGATIONAL PRODUCT FOR A PARTICIPANT  .................. 24 
6.3.1.  Neutropenia  .......................................................................................................................................... 25 
6.3.2.  Thrombocytopenia  ............................................................................................................................... 25 
6.3.3.  Renal Impairment  ................................................................................................................................. 25 
6.3.4.  Hepatotoxicity  ....................................................................................................................................... 26 
6.4. ACCOUNTABILITY PROCEDURES FOR THE STUDY INTERVENTION /INVESTIGATIONAL PRODUCT (S) ........ 26 
6.5. CONCOMITANT MEDICATIONS /TREATMENTS  ............................................................................................. 27 
6.5.1.  Co ncomitant Medication Assessment  ............................................................................................... 27 
6.5.2.  Prohibited Therapi[INVESTIGATOR_014]  ........................................................................................................................... 27 
6.5.3.  Drug Interactions  .................................................................................................................................. 28 
7. STUDY SCHEDULE  ............................................................................................................................... 29 
7.1. ENROLLMENT (WINDOW :  DAY -90 TO DAY -1) ......................................................................................... 29 
7.2. RANDOMIZATION AND BASELINE (WINDOW : DAY -1 TO DAY 1) ................................................................ 29 
7.3. TREATMENT (DAY 1 THROUGH DAY 42) .................................................................................................... 31 
7.4. FOLLOW -UP ................................................................................................................................................ 31 
7.4.1.  Day 14 ( ± 2 days)  ........................................................................................................................... 31 
7.4.2.  Day 28 ( ± 2 days)  ........................................................................................................................... 32 
7.4.3.  Day 42 ( ± 2 days)  ........................................................................................................................... 32 
7.4.4.  Day 70 ( ± 4 days)  ........................................................................................................................... 33 
7.4.5.  Month 4 ( ± 7 days)  .......................................................................................................................... 33 
7.4.6.  Month 6 ( ± 7 days)  .......................................................................................................................... 33 
7.5. FINAL STUDY VISIT .................................................................................................................................... 34 
7.6. EARLY TERMINATION VISIT ........................................................................................................................ 34 
7.7. UNSCHEDULED VISIT ................................................................................................................................. 34 
8. STUDY PROCEDURES/EVALUATIONS ............................................................................................. 35 
8.1. CLINICAL EVALUATIONS  ............................................................................................................................. 35 
8.1.1.  Baseline Demographics  ...................................................................................................................... 35 
8.1.2.  Growth ................................................................................................................................................... 35 
8.1.3.  Adverse Event Assessment  ................................................................................................................ 35 
8.1.4.  Hearing Assessment  ........................................................................................................................... 36 
8.2. LABORATORY EVALUATIONS  ...................................................................................................................... 36 
8.2.1.  Clinical Laboratory Evaluations  .................................................................................................... 36 
8.2.2.  Special Assays or Procedures  ...................................................................................................... 37 
8.2.3.  Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007]  ........................................................................ 38 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 _____________________________________________________________________________________________  
vi 9. DMID SAFETY REPORTING AND SAFETY MONITORING  ............................................................... 39 
9.1. RESPONSIBILITIES  ......................................................................................................................................  39 
9.2. ADVERSE EVENT (AE)  ............................................................................................................................... 39 
9.2.1.  Definition of an Adverse Event  ..................................................................................................... 39 
9.2.2.  Documentation of Reportable Adverse Events  .......................................................................... 39 
9.3. INVESTIGATOR ’S ASSESSMENT OF ADVERSE EVENT  ................................................................................ [ADDRESS_128246]  ........................................................................... 40 
9.4. STUDY RELATED ADVERSE EVENTS  ......................................................................................................... 41 
9.5. SERIOUS ADVERSE EVENT (SAE)  .............................................................................................................  [ADDRESS_128247]  ............................................................................................... 46 
10. CLINICAL MONITORING  .................................................................................................................. 47 
10.1.  SITE MONITORING PLAN ............................................................................................................................ 47 
11. STATISTICAL CONSIDERATIONS  .................................................................................................. 48 
11.1.  STUDY HYPOTHESES  ................................................................................................................................. 48 
11.2.  SAMPLE SIZE CONSIDERATIONS  ................................................................................................................ 48 
11.3.  PLANNED INTERIM ANALYSES (IF APPLICABLE ) ......................................................................................... 48 
11.3.1.  Safety  Review  ................................................................................................................................. 48 
11.3.2.  Immunogenicity or Efficacy Review  ............................................................................................. 49 
11.4.  FINAL ANALYSIS PLAN ............................................................................................................................... 49 
11.4.1.  Primary Outcome  ............................................................................................................................ 49 
11.4.2.  Secondary and Tertiary Outcomes  .............................................................................................. 50 
12. SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ............................... 51 
13. QUALITY CONTROL AND QUALITY ASSURANCE  ...................................................................... 52 
14. ETHICS/PROTECTION OF HUMAN SUBJECTS  ............................................................................ [ADDRESS_128248]  ................................................................................................................. 53 
14.3.  INFORMED CONSENT PROCES S ................................................................................................................ 54 
14.3.1.  Informed Consent/Assent Process (in Case of a Minor)  ........................................................... 54 
14.4.  EXCLUSION OF WOMEN , MINORITIES , AND CHILDREN (SPECIAL POPULATIONS ) .................................... [ADDRESS_128249] CONFIDENTIALITY  ....................................................................................................................... 55 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128250] KEEPI[INVESTIGATOR_1645]  .................................................................................. 57 
15.1.  DATA MANAGEMENT RESPONSIBILITIES  .................................................................................................... 57 
15.2.  DATA CAPTURE METHODS  ........................................................................................................................ 58 
15.3.  TYPES OF DATA ......................................................................................................................................... 58 
15.4.  TIMING /REPORTS  ....................................................................................................................................... 58 
15.5.  STUDY RECORDS RETENTION  ................................................................................................................... 58 
15.6.  PROTOCOL DEVIATIONS  ............................................................................................................................ 58 
16. PUBLICATION POLICY ..................................................................................................................... 60 
17. LITERATURE REFERENCES ........................................................................................................... 61 
SUPPLEMENTS/APPENDICES  .................................................................................................................... 63 
APPENDIX A: SCHEDULE OF EVENTS  ...................................................................................................... 64 
APPENDIX B:  DIVISION OF AIDS TOXICITY TABLES ............................................................................. 65 
 
 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128251] OF ABBREVIATIONS 
ACIP  Advisory Committee for Immunization Practices  
ADME  Absorption, Distribution, Metabolism and Elimination  
AE Adverse Event/Adv erse Experience  
AGA  Appropriate for Gestational Age  
AIDS  Acquired Immunodeficiency Syndrome  
ANC  Absolute Neutrophil Count  
AUC  Area Under the Curve  
BBB Blood -Brain Barrier  
BBU Biostatistics and Bioinformatics Unit  
BID Twice Daily  
BSER  Brainstem Evok ed Response  
CASG  Collaborative Antiviral Study Group  
CAVH  Continuous Arterio -Venous Hemofiltration  
CAVHD Continuous Arterio-Venous Hemodialysis  
CAVHDF  Continuous Arterio Venous Demodiafiltration   
CDC  Centers for Disease Control  
CFR Code of Federal R egulations  
CMV  Cytomegalovirus  
CNS  Central Nervous System  
CrCL  Creatinine Clearance  
CONSORT  Consolidated Standards of Reporting Trials  
CRF Case Report Form  
CRO  Contract Research Organization  
CROMS  Clinical Research Operations and Management Support  
CRRT  Continuous Renal Replacement Therapy  
CSF Cerebrospi[INVESTIGATOR_114708], NIAID,  NIH, 
DHHS  
DPOAE  Distortion Product Otoacoustic Emission  
DSMB  Data and Safety Monitoring Board  
eCRF  Electronic Case Report Form  
ESRD  End-stage Renal Disease  
EUA Emergency Use Authorization  
FDA Food and Drug Administration  
FWA  Federalwide Assurance  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128252]  
HIV Human Immunodeficiency Virus  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmon isation  
ICU Intensive Care Unit  
IDE Investigational Device Exemption  
IDMS  Isotope Dilution Mass Spectrometry  
IEC Independent or Institutional Ethics Committee  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Sa fety Monitor  
ITT Intent to Treat  
IV Intravenous  
KG Kilogram  
MeDRA  Medical Dictionary for Regulatory Activities  
MG Milligram  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_19737])  
N/A Not Applicable  
NCS  Not Clinically Significant  
NDA  New Drug Application  
NIAID  National Institute of Allergy and Infectious Diseases, NIH, DHHS  
NIH National Institutes of Health  
NOAEL  No Adverse Effect Level  
OAE  Otoacoustic Emissions  
OCRA  Office of Clinical Research Affairs, DMID, NIAID, NIH, DHHS  
OHRP  Office for Human Research Protections  
OHSR  Office for Human Subjects Research  
ORA  Office of Regulatory Affairs, DMID, NIAID, NIH, DHHS  
PCR  Polymerase Chain R eaction  
PD Pharmacodynamic  
PHI Protected Health Information  
PI [INVESTIGATOR_114709] #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 _____________________________________________________________________________________________  
x RNA  Ribonucleic Acid 
SAE Serious Adverse Event/Serious Adverse Experience  
SAS Statistical Analysis Software  
Scr Serum Creatinine  
SDW  Source Document Worksheet  
S&DCC  Statistical and Data Coordinating Center  
SMC  Safety Monitoring Committee  
SNHL  Sensorineural Hearing Loss  
SOP  Standard Operating Procedure  
STI Sexually Transmitted Infections  
TEOAE  Transient Evoked Otoacoustic Emission  
US [LOCATION_002]  
USP United State s Pharmacopeia  
VRA Visual Reinforcement Audiometry  
WHO  World Health Organization  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 _____________________________________________________________________________________________  
xi PROTOCOL SUMMARY  
Title:  A Phase II Randomized and Controlled Investigation of Six 
Weeks of Oral Valganciclovir Therapy in Infants  and Children 
with Congenital Cytomegalovi rus Infection and Hearing Loss  
Phase:  II 
Population:  Fifty-four male and female infants /toddlers  1 month through 3 
years  of age  (up to the 4th birthday)  with sensorineural hearing 
loss and congenital CMV infection.  Up to 20% (n= 10) over -
enrollment is allowed to replace subjects who drop-out or who have inadequate audiology assessments.  Subjects will be 
randomized 1:1 to Investigational  drug or placebo.  
Number of Sites:  17 (listed in Section 1)  
Study Duration:  3.[ADDRESS_128253] Participation 
Duration:  6 months  
Description of Agent or 
Intervention:   
Investigational Drug:  Valcyte (valganciclovir hydrochloride) 
Powder for oral solution:   
16.0 mg/kg twice daily  
 
Placebo: Simple Syrup as 60-90% sucrose  
Objectives: 
  
Primary: 
• The primary objective is to assess whether a six week 
course of oral valganciclovir can stabilize the hearing of children with congenital CMV infection who present with hearing loss.  This will be accomplished by [CONTACT_114761] 6 months from baseline.  
Secondary:  
• To define the following responses as a function of systemic 
exposure to ganciclovir (active metabolite of valganciclovir):  
o CMV viral load in blood  
o CMV viral load in urine  
o CMV viral load in saliva  
• To define the safety and tolerability of valganciclovir in enrolled subjects . 
Tertiary:  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 _____________________________________________________________________________________________  
xii • To define the pharmacokinetics of ganciclovir (metabolite) 
following administration of valganciclovir (prodrug) in 
enrolled subjects . 
Outcome Measures:  Primary Endpoint:  
• Change in total ear hearing assessments (improved + no 
change versus other ) between Baseline and Study Month 6 
Secondary Endpoints:  
• Change in best ear hearing assessments [improved + no change (normal to normal) versus other; improved versus other; worse + no change (abnormal to abnormal) versus 
other; and worse versus other] between Baseline and Study 
Month 6 
• Change in total ear hearing assessments (improved versus other; worse + no change (abnormal to abnormal) versus 
other; and worse versus other ) between Bas eline and Study 
Month 6 
• Detection of viruria by [CONTACT_114762]  
• The quantitative log reduction in viruria detected after 6 weeks of therapy  
• Detection of viremia by [CONTACT_114762]  
• The quantitative log reduction in viremia detected after 6 weeks of therapy  
• Detection of CMV in saliva by [CONTACT_114762]  
• The quantitative log reduction in CMV viral load in saliva detected after 6 weeks of therapy  
• Correlation of change in  viral load with change in total ear 
and best ear hearing at 6 months  
• Incidence of unanticipated medically attended visits 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128254] dose of study drug  
• Incidence of adverse events which lead to permanent 
discontinuation of valganciclovir therapy or  have an 
unresolved outcome 
Tertiary Endpoints:  
• Blood concentrations of ganciclovir after administration of 
valganciclovir  
Description of Study 
Design: This is an international, multi -center, double-blind, placebo-
controlled evaluation of 6 weeks of valganciclovir treatment for 
children (up to 4 years of age) with virologically -confirmed 
congenital CMV infection and hearing loss.  Patients who are 
between [ADDRESS_128255]’s  Guthrie card will be retrieved and tested for CMV 
DNA by [CONTACT_114763] a virologically confirmed diagnosis 
of congenital CMV infection made within the first [ADDRESS_128256] then is assigned to either receive 6 weeks of oral valganciclovir or 6 
weeks of placebo.  Study subjects will be stratified according to 
age at randomization (1 through 11 months, 12 through 23 
months, 24 through 35 months, and ≥ 36 months ) and CMV 
involvement (symptomatic and asymptomatic at birth) as a marker of disease severity.  The sample size of randomized, evaluable subjects is 54.  D ropouts and subjects with audiology 
assessments that are inadequate for study comparison will be replaced (up to 20%, or n=10).  Baseline study assessments 
(see Section 7.2) will be performed following randomization.  
Subjects will be followed for [ADDRESS_128257] randomization.  
During the six week treatment period, study subjects will be 
followed every 2 weeks.  Subjects will also be seen at  approximately one month following the final dose (Study Day 
70), and again at Study Months 4 and 6. 
At each of the visits during the treatment phase (Study Days 1, 
14, 28, and 42), safety labs will be assessed ; viral load 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 _____________________________________________________________________________________________  
xiv specimens from blood, urine, and saliva will be obtained; 
adverse events will be assessed ; and concurrent medications 
will be recorded.  Ganciclovir concentrations for population 
pharmacokinetic assessment will be obtained at each study visit 
while the subject is receiving study medication.  Dose 
adjustments for weight change will occur at study visits during 
the subject’s treatment period, and may also occur at any time 
during the treatment period as indicated per protocol for 
neutropenia, thrombocytopenia, or renal impairment.  At the Study Day 70 visit, safety labs will be obtained; viral load 
specimens from blood, urine, and saliva will be obtained; adverse events will be assessed ; and concurrent medications 
will be recorded.  Hearing will be assessed at baseline and at 
Study Month 6. 
Changes in whole blood viral load measurements will be correlated with hearing outcomes .  In study subjects with 
increasing whole blood viral loads during the course of 
treatment, antiviral resistance may be evaluated.  A Data and 
Safety Monitoring Board (DSMB) will be established to oversee the accrual, performance, safety, and efficacy of the trial.  
Estimated Time to 
Complete Enrollment:  3.[ADDRESS_128258] 
 
Collabor ative Antiviral Study Group          DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler              28 April 2016  
 
 __________________________________________________________________________________________________________________________________  
i *Schematic of Study Design:  
 
 
 
 
 
 
 
Month [ADDRESS_128259]  
Timing of study visits (days, months) for collection of urine, saliva, and blood (together with safety laboratory measurement s at Study Days 1, 14, 
28, 42 and 70)  Clinical Hearing 
Test 
Study Drug  Enrollment (signing of Informed 
Consent ): 
Evaluation of Guthrie Cards or other 
documentation of congenital CMV  Randomization   Baseline 
Assessments, including baseline hearing test  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
1 
 1. KEY ROLES 
Individuals:   
Protocol Clinical Project Manager : 
Walla Dempsey, PhD 
Division of Virology  
DMID/NIAID/NIH  
Division of Microbiology and Infectious Diseases, NIAID, NIH  
Room 8E575601 Fishers Lane  MSC 9825  Bethesda, MD  [ZIP_CODE]- 9825 
Phone: [PHONE_2596] 
[EMAIL_2259]  
 Principal Investigator:  
[INVESTIGATOR_10086] W. Kimberlin, M.D. 
Protocol Chair  
Co-Principal Investigator, NIAID Collaborative Antiviral Study 
Group  
Professor of Pediatrics  
Sergio Stagno Endowed Chair in Pediatric Infectious Diseases  
The University of Alabama at Birmingham  
[ADDRESS_128260] South, CHB 303 Birmingham, AL  [ZIP_CODE] Phone: [PHONE_2597] 
Phone: [PHONE_2598] (direct line)  
FAX: [PHONE_2599] 
e-mail:  [EMAIL_2260]
 
 Clinical Studies Manager  
Penny Jester, RN, MPH, CCRA  
Collaborative Antiviral Study Group 
The University of Alabama at Birmingham  
[ADDRESS_128261] South, CH B 303  
Birmingham, AL  [ZIP_CODE] 
Phone: [PHONE_2597] 
Phone: 205-996- 7800(direct line)  
Cell:    205- 329-3732 
FAX: [PHONE_2599] 
e-mail:  [EMAIL_2261]  
Medical Monitor:   Venus Shahamatdar, M.D.  
Office of Clinical Research Affairs  
Division of Microbiology and Infectious Diseases, NIAID, NIH  [ADDRESS_128262], 7E54,   
Bethesda, MD  [ZIP_CODE] -9826  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
2 
 Phone:  [PHONE_2600]   
Email: [EMAIL_2262]  
Institutions:   
University of Alabama at Birmingham  
David W. Kimberlin, M.D.  
Department of Pediatrics, Division of Infectious Diseases   
[ADDRESS_128263] South, CHB 303   
Birmingham, AL [ZIP_CODE]  Phone: [PHONE_2597]  Fax: 205-975 -9972  
Email: [EMAIL_2263]
  
 
University College London Medical School  
Paul Griffiths, M .D. 
UCL Medical 
School  
Royal Free Campus  
 Centre for Virology 
Rowland Hill Street 
London, [LOCATION_006] NW3  
2PF Phone: 020-
7830-2997 
Fax: 020-7830-2854 
Email:  [EMAIL_2264]. uk 
 
Carolinas Medical Center - Charlotte  
Amina Ahmed, M.D. B.S.  
Department of Pediatrics   
[ADDRESS_128264] MEB -4th  
Charlotte, NC [ZIP_CODE]  
Phone: [PHONE_2601]  Fax: 704-381 -6841 
Email: [EMAIL_2265]
  
 University  of Utah School of Medicine 
Kwabena Ampofo, MD  
[ADDRESS_128265]  SOM Room # 2A100 
Salt Lake City, UT  [ZIP_CODE] 
Phone: [PHONE_2602] Fax: 801-585 -3789 
Email:  [EMAIL_2266]
  
 Johns Hopkins Medical Institutions  
Ravit Boger, MD    
Division of Pediatric Infectious Diseases   
Rubinstein Child Health Building, [ADDRESS_128266]  
Room 3153   
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
3 
 Baltimore, MD [ZIP_CODE]   
Phone: [PHONE_2603]  
Fax: 410-614 -1491  
Email: [EMAIL_2267]   
 University of [COMPANY_002]ster Medical Center   
Mary Caserta, M.D.   
[ADDRESS_128267]  Box 690   [COMPANY_002]ster, NY [ZIP_CODE]  Phone: [PHONE_2604]  
Fax: 585-273 -1104  
Email: [EMAIL_2268]
  
 
The Newcastle upon Tyne Hospi[INVESTIGATOR_114710], Newcastle Upon Tyne,  NE4 6BE  
Phone: 0 [PHONE_2605]  Fax: 0 [PHONE_2606]  Email: 
 [EMAIL_2269]   
 Children's National Medical Center   
Roberta L. DeBiasi, MD   
[ADDRESS_128268] Wing 3.5   
Washington, DC [ZIP_CODE]  Phone: [PHONE_2607]  Fax: 202-476 -3850  
Email: [EMAIL_2270]
 
 Rhode Island Hospi[INVESTIGATOR_114711], MD  Division of Pediatric Infectious Diseases   
[ADDRESS_128269]      PO Box RM 018  Providence, RI [ZIP_CODE]  
Phone: [PHONE_2608]  
Fax: 401-444 -5650  
Email: [EMAIL_2271]
  
 
University  Hospi[INVESTIGATOR_114712] N Faust, 
NIHR Wellcome  Trust Clinic al Facility  
University  of Sout hampton, 
C Level, West Wing, Mailpoint 218, 
University Hospi[INVESTIGATOR_114713] #11- 0069, Version 4.[ADDRESS_128270],  
Southampt on,  
Hampshire SO16  6YD 
Phone: 023 8079 4989  
Fax: 023 8079 5023 
Email:  [EMAIL_2272]  
 
University Hospi[INVESTIGATOR_114714], BS2 8AE 
Phone: 44 (0)  
117 342  0207 
Fax: 44 (0) [PHONE_2609] 
Email:  [EMAIL_2273]    
 
Heart of England NHS Foundation Trust Scott Hackett, BSc, MD, MB ChB, MRCP, DTM&H Birmingham Heartlands Hospi[INVESTIGATOR_114715], B9 5SS  
Phone: +44 [PHONE_2610] 
Fax: +44 [PHONE_2611] Email:  [EMAIL_2274]
  
 Oxford University Hospi[INVESTIGATOR_114716], University of Oxford  Level 4, John Radcliffe Hospi[INVESTIGATOR_114717], Oxfordshire OX3 9DU   
Phone: 44 (0)1865 231693  Fax: 44 (0)1865 234235  Email: [EMAIL_2275]
  
 Ohio State University – Nationwide Children’s Hospi[INVESTIGATOR_114718], MD   
Center for Perinatal Research The Research Institute at Nationwide Children’s Hospi[INVESTIGATOR_307] 700 Children’s Drive, RB3WB5215 Columbus, OH   [ZIP_CODE]- 2664  
Phone: [PHONE_2612]  Fax: 614-3 55-5899  
Email: [EMAIL_2276]
  
 
St. George's University Hospi[INVESTIGATOR_114719] #11- 0069, Version 4.[ADDRESS_128271]    
Tooting, London SW17 0QT   
Phone: [PHONE_2622]  
Fax: [PHONE_2623]  
Email: [EMAIL_2277]   
 
Steven & Alexandra Cohen Children’s Medical Center of [LOCATION_001] (CCMC)  
Sunil Sood, MD   
[ADDRESS_128272]   
9 Tower North Shore University Hospi[INVESTIGATOR_307], Room 8   
Manhasset, NY [ZIP_CODE]  Phone: [PHONE_2613]  Fax: 516-562 -3958  
Email: [EMAIL_2278]
  
 Washington University in St Louis School of Medicine  
Gregory Storch, M.D.   
School of Med. at St. Louis Children's Hospi[INVESTIGATOR_307]   
[ADDRESS_128273]. Louis, MO [ZIP_CODE]  
Phone: [PHONE_2614]  Fax: 314-747 -1404  
Email: [EMAIL_2279]
  
 
Great Ormo nd Street Hospi[INVESTIGATOR_114720], M.D.  
Infectious  Diseases  and Immunology 
Institute of Child  Health and 
Great Ormo nd Street Hospi[INVESTIGATOR_114721] 
[ADDRESS_128274],   
London WC1N 1EH  
Phone: 0207 905 2891  
Fax: 0 [PHONE_2615] 
Email:  [EMAIL_2280]  
 
The Pennine Acute Hospi[INVESTIGATOR_114722], Manchester  
[CONTACT_114843] McMaster 
Consultant in Paediatric Infectious Diseases  
Limbert House 
North Manchester General Hospi[INVESTIGATOR_114723]’s  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128275]: 0161 922 3880 
Fax: 0161 922 3990 
Mobile: [ZIP_CODE] 753 768 Switch: 0161 624 0420 
E-mail: [EMAIL_2281]
 
 
Sheffield Children's NHS Foundation Trust  
[CONTACT_114844] disease and immunology  
Sheffield Children's Hospi[INVESTIGATOR_114724]'s NHS Foundation Trust Western Bank  
Sheffield. S10 2TH  
Direct: 0114 2717172 
Fax: 0114 271 7672 
Mobile: [ZIP_CODE] 554327 
Switch: 0114 271 7000 
E-mail: [EMAIL_2282]  
Statistical and Data 
Coordinating Center 
(SDCC) :  
Statistician: Inmaculada "Chichi" Aban, PhD  
Associate [CONTACT_3348] of Biostatistics  
School of Public Health  
The University of Alabama at Birmingham  
RPHB 327  
Phone: ([PHONE_2616] 
Fax: ([PHONE_2617] 
e-mail:  caban@ uab.edu 
 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
7 
 2. BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE  
2.1. Background Information  
Congenital cytomegalovirus (CMV) infection is the most frequent known viral cause of mental 
retardation,[ADDRESS_128276] common congenital infection in 
humans, with approximately 1% of all live births in the [LOCATION_002] being infected with CMV (~ 40,000 babies per year).
5  CMV can be acquired in utero during any trimester of pregnancy.  Of 
those fetuses infected, approximately 10% will be symptomatic at birth, and ~ 20% of these 
patients will die in the neonatal period; of the survivors, 90% will have significant neurologic 
sequelae.6-[ADDRESS_128277] sensorineural hearing loss, mental 
retardation, microcephaly, seizures, and/or paresis/paralysis.  These impairments frequently 
result in spastic quadriplegia requiring lifelong dependence on a wheelchair, along with 
cognitive and speech impairments which dramatically limit their ability to interact with and function in the world.  Patients with this degree of neurologic impairment generally have a life 
expectancy of less than ten to fifteen years.  
  
Children born with congenital CMV infection but without overt symptoms may nevertheless 
develop sequelae on follow -up, particularly sensorineural hearing loss.  A recent systematic 
review of all prospective studies published worldwide reports that 13.5% of babies with 
congenital CMV infection develop sensorineural hearing loss on follow -up.
[ADDRESS_128278] 40% of babies born with asymptomatic CMV infection will have delayed-onset hearing loss, as illustrated in the following table:
13 
 
Characteristics of Audiologic Sequelae in Congenital CMV Infection and Disease  
  Sequelae       Symptomatic   Asymptomatic  
Sensorineural hearing loss     41% (85/209)    7.4% (48/651) 
Characteristics of loss  
 Unilateral loss       33% (28/85)     52% (25/48) 
 Bilateral loss       67% (57/85)     48% (23/48) 
 High frequency loss only     13% (11/85)     38% (18/48) 
 Delayed-onset loss      27% (23/85)     38% (18/48) 
 Progressive loss      54% (46/85)     54% (26/48) 
 Fluctuating loss      29% (25/85)     54% (26/48) 
 Improvement of loss      21% (18/85)     48% (23/48) 
 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
8 
 Furthermore, the overwhelming majority who will develop delayed-onset hearing loss do so by 4 
years of age:13 
 
Cumulative Percentage of Sensorineural Hearing Loss, by [CONTACT_114764] – 1 month            43.5%           25.5%  
3 months              55.3%           31.4%  
6 months              67.2%           43.1%  
2 years              82.4%           47.1%  
3 years              88.2%           58.8%  
4 years              89.4%           72.5%  
6 years              95.3%           86.6%  
7 – 15 years              100%           100%  
 The overall societal costs of providing specialized services for surviving infants and children with 
congenital CMV infections are in the billions of dollars annually.
[ADDRESS_128279].  
2.1.1.  Retrospective diagnosis of congenital CMV  
Clinical investigators are now diagnosing congenital CMV infection retrospectively when older children present with hearing loss by [CONTACT_114765] ( DBS; 
Guthrie cards) which had been obtained during the neonatal period.  While the sensitivity of DBS PCR is variable (34 -100%), the specificity is high (99-100%) such that a positive result 
confirms congenital CMV infection while a negative result does not rule out a congenital CMV infection.
16,[ADDRESS_128280] negative results (specificity 100%) and [ADDRESS_128281] 
positive results (sensitivity 100%).  Compared to the viral load found in each fresh whole blood, 
the viral load from the DBS was initially approximately [ADDRESS_128282] 2 years.  These results show that the sensitivity of DBS is slightly lower than that of whole blood (cut-off 1000 genomes/ml vs 200 genomes/ml) but that DBS retrieved from children of the 
age required for this study should give reliable results.  Additionally, the stored DBS of 39 
children (aged 2 months -13 yrs at time of testing) with proven congenital CMV infection and 
sensorineural hearing loss were retrieved, together with those from 35 children (aged 7months 
to 15years) with unexplained SNHL.  These samples were tested under code by [CONTACT_114766].  The sensitivity was 75% (28/39 known cases  of congenital infection) while 23% (8/35) of 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
9 
 cases of unexplained SNHL were PCR positive (similar to results of 20% and 25% previously 
reported for qualitative PCR).  One case of a false-positive reaction was seen (child and mother 
both CMV seronegative).  Importantly, a defined threshold effect was seen when severity of hearing loss was plotted against CMV viral load in DBS.  However, the shape of this curve was 
so steep that, for practical purposes, the detection of any level of viremia could be considered a 
risk factor for future hearing loss, as previously reported by [CONTACT_114767] (CASG).
19  We conclude from all these results that ongoing CMV replication may 
be a risk factor for progressive hearing loss and that control of viral replication may be considered a potential pharmacodynamic measure of successful antiviral therapy.  
2.1.2.  Treatment  of Congen ital CMV  
CYTOVENE-IV (ganciclovir)  is indicated for the treatment of CMV retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS) a nd for the prevention of CMV disease in transplant recipi[INVESTIGATOR_114725].  
In adults, VALCYTE (valganciclovir) is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for the  prevention of CMV disease in kidney, heart, or kidney -pancreas transplant  patients at high risk.  
In pediatric patients,  valganciclovir is indicated for the prevention of CMV disease in kidney or heart transplant patients at high risk.  
There are no FDA approved therapi[INVESTIGATOR_114726].  Both intravenous ganciclovir and 
oral valganciclovir have been evaluated previously for the treatment of neonates with symptomatic congenital CMV.  Several studies conducted by [CONTACT_114768].  
[IP_ADDRESS].    Evaluations of Ganciclovir  and Valganciclovir  
In one phase III study, 100 neonatal subjects were randomized to receive either 6 weeks of IV 
ganciclovir  or no therapy .20  The primary study endpoint was improved brain stem evoked 
response (BSER) audiometry by [CONTACT_114769] 6 month follow -up (or, 
for those patients with normal hearing at baseline, normal BSER at both timepoints).  Measures of clinical and laboratory improvement constituted the secondary endpoints, and growth was the 
tertiary endpoint of the trial.  Audiologic analyses were performed on best evaluable ear 
(“functional” assessment) and on total evaluable ears (“biologic” assessment).  The best ear assessment correlates with functional hearing impairment in daily living (e.g., a person with mild hearing impairment in one ear and severe hearing impairment in the other ear will function 
essentially as a mildly hearing impaired person).
21,22  Total ear assessment further assesses the 
biologic effects of ganciclovir therapy.  Of these 100 subjects, 42 patients met all study entry 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
10 
 criteria, had both a baseline and 6 month follow -up BSER audiometric exam, and thus were 
evaluable for the primary endpoint.   
 
Twenty -one (84%) of [ADDRESS_128283] ear between baseline and 6 months or had normal hearing at both timepoints, compared with 10 (59%) of 17 evaluable  patients in the no treatment group [adjusted P -value = 
0.06; OR 5.03 (95% CI: 0.84,45.94)].  Inclusion in the best-ear analysis of two additional 
patients who did not meet all entry criteria yielded an adjusted P -value of 0.03.  None (0%) of [ADDRESS_128284] ear between baseline and 6 
months, compared with 7 (41%) of 17 patients in the no treatment group [adjusted P -value < 
0.001; OR 21.11 (95% CI: 2.84,∞ )].  Five (21%) of [ADDRESS_128285] ear between baseline and ≥  1 year, compared with 13 (68%) of 19 patients 
in the no treatment group [adjusted P -value = 0.002; OR 10.26 (95% CI: 1.79,81.92)].  
Ganciclovir -treated patients had a more rapid median time to normalization of ALT (19 days) 
compared with patients in the no treatment group (66 days) (P = 0.03).  Ganciclovir -treated 
patients had a greater degree of weight gain (P = 0.02) and growth in head circumference (P < 
0.01) at six weeks following study enrollment than did patients who did not receive antiviral therapy.  
 Laboratory abnormalities reported during the study, were assessed by [CONTACT_114770] 3-4 toxicity utilizing NIAID Division of AIDS (DAIDS) toxicity tables. The most frequent 
adverse event was neutropenia, which was experienced by a markedly higher proportion of 
patients on the IV ganciclovir arm of the study.
20  Twenty -nine (63%) of 46 ganciclovir -treated 
patients developed Grade 3 or 4 neutropenia during the six weeks of study drug administration, 
compared with 9 (21%) of 43 patients in the no treatment group over the same period of time (P 
< 0.01).  Dose adjustments were required for neutropenia in fourteen (48%)subjects, although 
only 4 patients had the drug permanently discontinued.  The mean time ( ± SD) of onset of grade 
3 or 4 neutropenia for patients receiving ganciclovir was 14.2 ( ± 12.3) days, and for the no 
treatment group was 14.3 ( ± 13.1) days.  Neutropenia in ganciclovir -treated patients resolved in 
12.8 (±  13.6) days, and in the no treatment group in 14.2 ( ± 13.5) days.  All affected patients 
resolved their neutropenia.  Anemia was also more common in patients who received IV 
ganciclovir (8%, vs. 3% untreated patients), although the incidence of thrombocytopenia 
appeared comparable in the two treatment groups (2% i.v. g anciclovir treated patients vs. 3% 
untreated patients). The incidence of bloodstream infections, hematochezia, and diarrhea was 
also higher in patients who received IV ganciclovir.  The incidence of a Grade 3-4 increase in 
serum creatinine, alanine amino transferase (ALT), and total bilirubin levels was comparable 
between groups. 
 
In summary, ganciclovir treatment of neonates with symptomatic congenital CMV disease involvi ng the CNS indicates that ganciclovir therapy both improves hearing function (or 
maintains normal hearing) and prevents hearing deterioration at 6 months.  Furthermore, 
ganciclovir therapy may prevent hearing deterioration at ≥  1 year.  Ganciclovir recipi[INVESTIGATOR_114727] #11- 0069, Version 4.[ADDRESS_128286] 
closely related to virologic treatment success.
23   In adults, valganciclovir, the mono-valyl ester 
pro-drug of ganciclovir is well absorbed and converted rapi[INVESTIGATOR_114728].  The NIAID CASG therefore conducted a Phase I/II pharmacokinetic/pharmacodynamic investigation of oral 
valganciclovir in infants with symptomatic congenital CMV disease.
24  Twenty -four subjects 
under one month of age with symptomatic congenital CMV disease were enrolled.  All subjects received antiviral treatment for congenital CMV, either predominantly with IV  ganciclovir and 
with intermittent doses of oral v alganciclovir , or predominantly with oral valganciclovir.  
 
Based on data from a previous phase II study of intravenous ganciclovir  in neonates with symptomatic congenital CMV disease, a target  AUC
12 of 27 ugxh/mL (mean AUC 12=32.3+13.7 
ugxh/mL, range 17.2 to 55.9 ugxh/mL, n=13) was defined following treatment with a 6 mg/kg/dose q 12 hrs .
25  The evaluation of valganciclovir in the same population showed that a 
median dose of oral valganciclovir of 16 mg/kg provided a ganciclovir AUC 12 of 27.4 ugxh/mL.24  
The median half-life of valganciclovir in infants ranged between 2.5 to 3 hours.  This study also demonstrated that oral bioavailability of valganciclovir oral solution increases in early infancy (from 48% at approximately 4 weeks of life to 64% at approximately 7 weeks of life), and that 
this increase is proportionate to the increase in renal clearance of ganciclovir during the same 
period.  Thus, oral valganciclovir actually is a more reliable method of delivering ganciclovir to young infants than intravenous ganciclovir, since the increase in oral bioavailability 
“compensates” for the increase in ganciclovir clearance which occurs in the first few weeks to 
months of life, thereby [CONTACT_114771]. 
 
Oral valganciclovir was well tolerated with no vomiting.  The primary safety finding was the development of neutropenia.  Neutropenia of grade 3 or 4 developed in 38% (n=9) of study subjects treated with  oral valganciclovir and/or iv ganciclovir, but only [ADDRESS_128287] and 1 developed a grade 3 hyperbilirubinemia.  Eleven 
subjects on this study experienced SAEs (46%).  One (neutropenia) was assessed to be probably related to receipt of study medication; ten were assessed as unrelated.   
2.2. Rationale  
 Because of the progressive nature of congenital CMV -associated hearing loss, there is a large 
unmet medical need for treatment options beyond the neonatal period.  Data from other CASG 
investigations support the study of antiviral treatment in infants and toddlers with CMV -
associated hearing loss: 
• Less than half of the hearing loss due to congenital CMV infection is present at birth.4,13 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
12 
 • Children with congenital CMV continue to excrete virus in the urine for three to five years or 
even longer .26 
• The quantity of CMV (viral load) found in the urine and blood is greater in those children destined to develop hearing loss.
19,26,27 
• CMV DNA has been detected in the perilymph of children up to four years of age undergoing cochlear implantation for CMV -induced hearing loss.
28 
• Six weeks  of IV ganciclovir at 6mg/kg bid given to neonates with congenital CMV disease 
beginning when they are less than 31 days of age reduces the future incidence of hearing 
loss.20 
• Six weeks of intravenous ganciclovir given to neonates with congenital CMV disease 
beginning when they are less than 31 days of age suppresses viruria, as detected by [CONTACT_114772], but viruria returns promptly when the drug is stopped, even at the higher dose of 6mg/kg bid.
29 
• The dose of oral valganciclovir that provides the same systemic exposure as the IV ganciclovir dose used in treatment of congenital CMV has been identified, with 16 mg/kg/dose of oral valganciclovir equaling 6 mg/kg/dose of IV ganc iclovir.
[ADDRESS_128288] a similar difference in audiologic outcomes to that seen when ganciclovir was 
given for the same duration to neonates and young infants (i.e. worsening of hearing in 41% 
versus 0% was observed,20 whereas the more conservative difference of 40% versus 5% has 
been used for the power calculation for the current study).  Since the natural histories of CMV 
viruria and viremia have not been defined in older children, we anticipate generating valuable 
data on viral load as a potential biomarker in this population, even if the clinical primary endpoint 
of hearing is not met.  It is possible to envisage utilizing such biomarker data in the development of a future study evaluating a longer duration of valganciclovir or with safer medications.   
In the recently completed CASG [ADDRESS_128289] six weeks of therapy was associated 
with better hearing outcomes at 12 and 24 months in unadjusted (p=0.005 and p=0.003, respectively) and adjusted (p=0.044 and p=0.023, respectively) analyses.  However, lower whole blood viral load area-under -the-curve from week six to month six was not associated with 
hearing outcomes in adjusted analyses (p>0.168).  This suggests that lowering systemic viral load initially aids in improving audiologic outcomes, but that the additional benefit of longer -term 
treatment for six months may relate to antiviral effects within the inner ear itself, where ongoing viral replication and damage may be impaired with prolonged antiviral therapy. We were not 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128290] month of 
life.
20  As described above, treatment with oral valganciclovir has the potential benefit of 
improving hearing outcomes in children with congenital CMV infection and hearing loss who are 1 month through 3 years  of age.  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
14 
 3. OBJECTIVES 
3.1. Study Objectives  
Primary: 
• The primary objective is to assess whether a six week course of oral valganciclovir can 
stabilize the hearing of children with congenital CMV infection who present with hearing loss.  This will be accomplished by [CONTACT_114773] 6 months from 
baseline.  
 
Secondary:  
• To define the following responses as a function of systemic exposure to ganciclovir (active metabolite of valganciclovir):  
o CMV viral load in blood  
o CMV viral load in urine  
o CMV viral load in saliva  
• To define the safety and tolerability of valganciclovir in enrolled subjects. 
 
Tertiary:  
• To define the pharmacokinetics of ganciclovir (metabolite) following admini stration of 
valganciclovir (prodrug) in enrolled subjects . 
3.2. Study Outcome Measures 
3.2.1.  Primary Outcome Measure  
• Change in total ear hearing assessments (improved + no change versus other) between 
Baseline and Study Month 6 
3.2.2.  Secondary Outcome Measures  
• Change in best ear hearing assessments [improved + no change (normal to normal) versus 
other; improved versus other; worse + no change (abnormal to abnormal) versus other; and 
worse versus other] between Baseline and Study Month 6 
• Change in total ear hearing assessments (improved versus other; worse + no change 
(abnormal to abnormal) versus other; and worse versus other ) between Baseline and Study 
Month 6 
• Detection of viruria by [CONTACT_114774] #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
15 
 • The quantitative log reduction in viruria detected after 6 weeks of therapy  
• Detection of viremia by [CONTACT_114762]  
• The quantitative log reduction in viremia detected after 6 weeks  of therapy  
• Detection of CMV in saliva by [CONTACT_114762]  
• The quantitative log reduction in CMV viral load in saliva detected after 6 weeks of therapy  
• Correlation of change in viral load with change in total ear and best ear hearing at 6 months  
• Incidence of unanticipated medically attended visits occurring from Study Day [ADDRESS_128291] dose of study drug  
• Incidence of adverse events which lead to permanent discontinuation of valganciclovir therapy or  have an unresolved outcome  
3.2.3.  Tertiary Outcome Measures  
• Blood concentrations of ganciclovir after administration of valganciclovir  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
16 
 4. STUDY DESIGN  
This is a  Phase II international, multi -center, double-blind, placebo-controlled evaluation of 6 
weeks of valganciclovir treatment for children (up to 4 years of age) with virologically -confirmed 
congenital CMV infection and hearing loss.  Patients who are between [ADDRESS_128292]’s Guthrie card will be retrieved and tested for CMV DNA by [CONTACT_114763] a virologically confirmed diagnosis of congenital CMV infection 
made within the first [ADDRESS_128293] then is assigned to either receive 6 weeks of oral valganciclovir or 6 weeks of placebo.  Study subjects will be stratified according to age at randomization (1 through 11 months, 12 through 23 months, 24 
through 35 months, and ≥ 36 months ) and CMV involvement (symptomatic and asymptomatic at 
birth) as a marker of disease severity.  The sample size of randomized, evaluable subjects is 
54.  D ropouts and subjects with audiology assessments that are inadequate for study 
comparison will be replaced (up to 20%, or n=10).  Baseline study assessments (see Section 7.2) will be performed following r andomization.  Subjects will be followed for [ADDRESS_128294] 
randomization.  During the six week treatment period, study subjects will be followed every 2 
weeks.  Subjects will also be seen at approximately one month following the final dose ( Study 
Day 70), and again at Study Months 4 and 6. 
At each of the visits during the treatment phase (Study Days 1, 14, 28, and 42), safety labs will 
be assessed; viral load specimens from blood, urine, and saliva will be obtained; adverse 
events will be assessed; and concurrent medications will be recorded.  Ganciclovir concentrations for population pharmacokinetic assessment will be obtained at each study visit 
while the subject is receiving study medication.  Dose adjustments for weight change will occur 
at study visits during the subject’s treatment period, and may also occur at any time during the treatment period as indicated per protocol for neutropenia, thrombocytopenia, or renal 
impairment.  At the Study Day 70 visit, safety labs will be obtained; viral load specimens from 
blood, urine, and saliva will be obtained; adverse events will be assessed; and concurrent 
medications will be recorded.  Hearing will be assessed at baseline and at Study Month 6. 
Changes in whole blood viral load measurements will be correlated with hearing outcomes.  In 
study subjects with increasing whole blood viral loads during the course of treatment, antiviral 
resistance may be evaluated.  A Data and Safety Monitoring Board (DSMB) will be established to oversee the accrual, performance, safety, and efficacy of the trial.  
Study Day [ADDRESS_128295] dose of study 
medication is administered.  “Study drug” refers to valganciclovir or placebo (for six weeks).  
Follow -up visits referred to by [CONTACT_114775] 1 (e.g., if 
Study Day 1 is June 20, then Study Day 7 will be June 26); follow -up visits referred to by [CONTACT_114776] #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
17 
 Month will be determined by [CONTACT_114777] (e.g., if Study Day 1 is June 20, then Study Month 
1 will be July 20).   
4.1. Substudies (if applicable) 
None. 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
18 
 5. STUDY ENROLLMENT , RANDOMIZATION,  AND 
WITHDRAWAL  
5.1. Enrollment  
Male and female infants from 1 month through 3 years of age (up to 4th birthday) with 
sensorineural hearing loss  will be eligible for enrollment.  En rollment on the study occurs 
when eligibility is confirmed and the informed consent is signed.  Following confirmation of 
inclusion/exclusion criteria and the signing of informed consent, the subject’s Guthrie card will 
be retrieved and tested for CMV DNA by [CONTACT_114763] a virologically confirmed diagnosis 
of congenital CMV infection made within the first 30 days of life.  Enrollment will be implemented 
by [CONTACT_114778]-based enrollment system developed and maintained at the UAB Biostatistics Unit at 
the University of Alabama at Birmingham.  
Clinicians who care for these patients  (e.g., audiologists, otolaryngologists, pediatricians) will be 
made aware of the study so that they can inform the parents and guardians of patients with sensorineural hearing loss about the availability of the study.   
5.2. Subject Inclusion Criteria  
• Signed informed consent from parent(s) or legal guardian(s) 
• Sensorineural  hearing loss (≥ 21dB in one or both ears, documented within 12 weeks prior 
to study entry) 
• Children from 1 month through 3 years of age (up to the 4th birthday)  
5.3. Subject Exclusion Criteria 
• Imminent demise 
• Profound sensorineural hearing loss (> 90dB) in both ears  
• Patients  receiving other antiviral agents or immune globulin  
• Gastrointestinal abnormality which might preclude absorption of an oral medication (e.g., a history 
of necrotizing enterocolitis)  
• Documented renal insufficiency, as noted by a creatinine clearance < 10 m L/min/1.73m2 at time of 
study enrollment  
• Breastfeeding from mother who is receiving ganciclovir, valganciclovir, foscarnet, cidofovir, or maribavir 
• Infants known to be born to women who are HIV positive (but HIV testing is not required for study entry). 
• Current receipt of other investigational drugs 
• Previous receipt of ganciclovir or valganciclovir  
• Known hypersensitivity to ganciclovir, valganciclovir, or components of the product  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
19 
 • Inability to attend follow -up hearing and clinical assessments 
• Infants with A uditory neuropathy/dyssynchrony.  
• Children with another known  etiology for SNHL (e.g. connexin 26, syndrome or metabolic disorder 
associated with SNHL, inner ear malformation and widened vestibular aqueducts, meningitis).  
Exclusion of each of these conditions is not required for trial enrollment. 
5.4. Treatment Assignment Procedures  
5.4.1.  Randomization Procedures  
Randomization on the study occurs when the diagnosis of congenital CMV infection is 
confirmed, and the subject then is assigned to either receive 6 weeks of oral valganciclovir or 6 
weeks of placebo.  Study subjects will be stratified according to age at randomization (1 through 
11 months, 12 through 23 months, 24 through 35 months, and ≥ 36 months ) and CMV 
involvement (symptomatic and asymptomatic at birth) as a marker  of disease severity.  Age 
stratification is justified by [CONTACT_114779] 12 months versus toddlers 12 months and older.  D ropouts and subjects 
with audiology assessments that are inadequate for study comparison will be replaced (up to 20%, or n=10).   
Randomization will be implemented by [CONTACT_114778]-based randomization system developed and 
maintained at the UAB  Biostatistics Unit at the University of Alabama at Birmingham.  The 
generation and maintenance of study randomization codes will be the responsibility of the UAB  
Biostatistical Unit.  The codes will be kept in a secure location in the Biostatistics Unit. 
5.4.2.  Masking Procedures  
Study subjects, investigators, and staff interacting with the study subjects will be masked to 
treatment.  At the time of randomization, the site study pharmacist (who will not be masked to 
treatment) will prepare oral valganciclovir or oral placebo for distribution to the study subject.  To 
ensure masking of all other study staff and families, study drug will be dispensed in amber bottles, along with amber -colored syringes for drawing up all doses.  Additionally, the central 
audiologist who analyzes the audiology data will be masked to study assignment, as will all 
personnel at the UAB Central Unit (with the exception of the UAB Study Statistician).  
Upon completion of the six month follow -up period for all study subjects, or if the study is 
stopped early for any reason, the study will be unmasked after all enrolled study participants have completed the Month 6 follow -up assessments and the database is frozen.  In an 
emergency situation, in w hich knowledge of the treatment assignment will be used to 
reduce/remove an immediate hazard to a volunteer, the study PI [INVESTIGATOR_1238]/or a local site PI [INVESTIGATOR_114729].  In this situation (emergency unblinding) the 
study/l ocal PI [INVESTIGATOR_114730] #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
20 
 immediately unblind to the DMID Medical Monitor and the Protocol Chair as soon as possible.  
This justification will be documented as a protocol deviation, and the IRBs and regulatory 
agencies will be informed as is appropriate.  
 
Unmasking/Unblinding may also occur when the safety of a study participant is in question.  In 
non-emergency situations, a conference call will be held to determine whether or not unmasking of an individual study subject is necessary or appropriate.  The conference call will include the 
Protocol Chair, Protocol Statistician, DMID Medical Monitor and Clinical Project Manager. 
5.4.3.  Reasons for Withdrawal Before Randomization 
The criteria for discontinuation of study participation following enrollment and before 
randomization include:  
• Failure to confirm congenital CMV infection  
• Study subject (parent/legal guardian) wishes to withdraw  
• Trial termination (by [CONTACT_114780], FDA, DMID, NIAID, NIH, UCL, or  agreement of all 
investigators) issued per safety or efficacy criteria 
• Any other reason which, in the opi[INVESTIGATOR_871], precludes the study subject's 
participation in the study.  The principal investigator [INVESTIGATOR_114731] (or designee) prior to discontinuing a study subject for this reason. 
5.4.4.  Reasons for Withdrawal After Randomization and During Treatment  
The criteria for discontinuations during the treatment portion of the study include:  
• Development of a related serious adverse event warranting withdrawal of therapy  
• Study subject (parent/legal guardian) wishes to withdraw  
• Non-compliance with study procedures or medication schedule that in the opi[INVESTIGATOR_114732]  
• Deterioration in general condition for which alternative treatment is indicated and which, in 
the opi[INVESTIGATOR_871], warrants withdrawal  
• Trial termination (by [CONTACT_114780], FDA, DMID, NIAID, NIH, UCL, or agreement of all investigators) issued per safety or efficacy criteria 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
21 
 • Any other reason which, in the opi[INVESTIGATOR_871], precludes the study subject's 
participation in the study.  The principal investigator [INVESTIGATOR_114731] (or 
designee) prior to discontinuing a study subject for this reason. 
5.4.5.  Reasons for Withdrawal  After Randomization and After Completion 
of Treatment  
Criteria for discontinuing study subjects from the study after completion of the study medication 
are: 
• Study subject (parent/legal guardian) wishes to withdraw  
• Any other reason, which in the opi[INVESTIGATOR_871], should preclude the study 
subject's continued participation in the study.  The investigator must call the Protocol Chair  
(or designee)  prior to discontinuing a study subject for this reason.  
• Any subject that is terminated due to loss to follow -up will be considered as withdrawn 
5.4.6.  Handling of Withdrawals 
Study subjects may withdraw voluntarily from participation in the study at any time. Up to 20% 
(n=10) over -enrollment is allowed to replace subjects who drop-out or who have inadequate 
audiology assessments.   Study subjects also may withdraw voluntarily from receiving the study 
intervention for any reason.  If a study subject withdraws or is discontinued from the study at any time prior to completion of the study, the reason for this decision will be recorded on the 
electronic case report form (e CRF).  SAEs and AEs will be followed according to guidelines in 
Section 9.  The study subject should be encouraged to complete follow -up visits as part of the 
intent to treat group. 
Should a study subject’s therapy be discontinued prematurely, all clinical and laboratory 
evaluations scheduled during the next study visit will be completed on the day the study subject 
is discontinued.  All randomized study subjects will continue to be followed as long as possible 
and included in the final analysis.  
Since the primary endpoint requires comparison of baseline and 6 month audiology 
assessments, dropouts and subjects with audiology assessments that are inadequate for study 
comparison (Section 11.4.1) will be re placed.  Characteristics of the dropouts and those with 
missing outcomes will be compared to determine if there is a difference between the two 
treatment groups.  If differences are observed, this will be included in the primary outcome 
reporting as a limi tation.  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128296] the right to 
terminate this study at any time.  Reasons for terminating the study may include, but are not 
limited to, the following: 
• The incidence or severity of adverse events in this or other studies indicates a potential 
health hazard to study subjects  
• Study subject enrollment is unsatisfactory.  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
23 
 6. STUDY INTERVENTION/INVESTIGATIONAL PRODUCT  
6.1. Study Product Description  
 Valcyte Powder for Oral Solution (v alganciclovir ) is indicated for the treatment of CMV retinitis 
in adult patients with AIDS and for the prevention of CMV disease in adult and pediatric kidney, 
heart, and kidney -pancreas transplant recipi[INVESTIGATOR_114733].  Simple Syrup (Syrup, NF) will be 
used for the placebo for valganciclovir. 
6.1.1.  Acquisition 
Valcyte Powder for Oral Solution (v alganciclovir ) will be provided for this study by 
[CONTACT_8229]/[COMPANY_002].  Simple Syrup  (Syrup, NF) for  placebo will be purchased from a commercial 
vendor  by [CONTACT_779].  Study supply (active drug) will be maintained in a central drug repository as 
designated by [CONTACT_114781] a site, at which time the supply of 
study medication will be shipped to the study site pharmacist. 
6.1.2.  Formulation, Packaging, and Labeling 
Valcyte Powder for Oral Solution (valganciclovir) will be supplied as a white to slightly yellow 
powder for reconstitution.  The powder is provided in a round amber glass bottle, containing 12g 
powder containing 5g valgancyclovir free base.  Upon reconstitution, the resulting oral solution  
contains 50 mg of valganciclovir free base per 1 mL (Total = 100 mL per bottle).  The inactive 
ingredients for the reconstituted oral solution are mannitol, povidone K -30, sodium benzoate, 
fumaric acid, sodium  saccharin, flavoring, and purified or sterile  water.  The valganciclovir oral 
solution formulation does not contain lactose anhydrous.  
 Placebo for Valganciclovir  
The placebo for valganiclovir is Simple Syrup (Syrup NF), which contains 60-90% sucrose in 
purified water.  It is supplied as the commercial preparation. 
Valganciclovir and Simple Syrup (Syrup NF) will be labeled with the drug identification and 
dosage.  The label will comply with IND regulations, the local requirements of the country in 
which the study is being conducted and carry the required caution statement.  Blinded labeling 
of study product will be performed by [CONTACT_114782].  Valganciclovir will be dispensed in its original bottle.  Simple Syrup will be transferred to a 
matching amber bottle.  Study products (active or placebo)  will be dispensed in a new bottle at 
each study visit during the six weeks of study drug administration. 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128297] Storage and Stability  
Valganciclovir  will be provided as a powder  for oral solution .  Dry p owder is to be stored at 25ºC 
(77ºC ); excursions permitted to 15° C to 30° C (59°F to 86° F). Store reconstituted oral solution at 
2° to 8°C (36°F to 46° F) for no longer than 49 days. Do not freeze.  Shake bottle well before 
using.  
Simple Syrup placebo is to be stored at 2°  to 8°C (36°F to 46° F) for no longer than 49 days  
following dispensing for the study . 
6.2. Dosage, Preparation and Administration of Study 
Intervention/Investigational Product 
Valcyte Powder for Oral Solution (valganciclovir) will be prepared by a licensed pharmacist in 
accordance with instructions in the package insert.  Placebo for valganciclovir ( Simple Syrup) 
will be transferred from the commercial bottle to identical empty amber bottles for dispensing. 
Valganciclovir should be dosed at 16mg/kg body weight, unless specific dosage adjustment 
conditions have been met (see Section 6.3), administered orally twice daily for 6 weeks.  
Placebo for valganciclovi r (Simple Syrup) should be dosed using the same volume that would 
be required for the active dose, administered orally twice daily for [ADDRESS_128298] can be found in the protocol -specific 
Manual of Procedures (MOP), including directions  for the reconstitution of the valganciclovir oral 
solution.  Once reconstituted, the oral solution must be stored under refrigeration for no longer 
than 49 days.  Valganciclovir oral solution has been shown not to adhere to syringes or to 
nasogastric tubing.  Valganciclovir  oral solution or placebo for valganciclovir  should be 
administered into the patient’s mouth by [CONTACT_3553] a syringe, which will be amber colored and 
provided by [CONTACT_1758] .  If the patient is unable to swallow, the study product may be 
administered via the syringe through a nasogastric or gastric tube. 
Study product administration should  be timed to precede a feeding.  If the subject vomits or 
spi[INVESTIGATOR_114734], re-dosing will not  be allowed. 
6.3. Modification of Study Intervention/Investigational Product for a 
Participant 
Bone marrow suppression secondary to CMV can mimic ganciclovir toxicity.  Nevertheless, the 
dosage of valganciclovir will be reduced or interrupted if any of the following occur.  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
25 
 6.3.1.  Neutropenia 
If the ANC reproducibly  (within one week) decreases to ≤ 500 cells/mm3, study drug will be held 
until the ANC recovers to > 750 cells/mm3, and then administration of the drug will resume at 
the normal dose.  If the ANC again reproducibly (within one week) decreases to ≤  750 
cells/mm3, the study drug dosage will be reduced by 50% and maintained there as long as the 
ANC remains > 500 cells/mm3.  If the ANC reproducibly (within one week) decreases to ≤  500 
cells/mm3 on the 50% dosage, then the study medication will be discontinued.  In cases of drug 
interruption, treatment will not be prolonged beyond the originally scheduled 6 week treatment 
timeframe.  
Administration of granulocyte colony stimulating factor (GCSF) is allowed.  All administered 
GCSF doses will be recorded on the concomitant medication sheet.  The decision to utilize 
GCSF is left to the medical discretion of the participating investigator.  The parameters for dose 
adjustment stated above, based upon ANC, will remain in effect even if the patient is receiving GCSF.  
6.3.2.  Thrombocytopenia 
If the platelet count at baseline was ≥  100,000/mm3, then study drug will be held if the platelet 
count reproducibly (within one week) decreases to ≤  50,000/mm3.  After the platelet count 
increases to ≥ 50,000/mm3, study drug administration at the normal dose will resume. 
If the platelet count at baseline was ≤  100,000/mm3, then study drug will be held if the platelet 
count reproducibly (within one week) decreases by 50% from baseline value.  After the platelet 
count increases above 50%  from baseline value, study drug administration at the normal dose 
will resume.  If the platelet count again reproducibly (within one week) decreases by 50%, then 
the study medication will be discontinued.  In cases of drug interruption, treatment will not be 
prolonged beyond the originally scheduled 6 week treatment timeframe.  
6.3.3.  Renal Impairment  
If renal function is normal (creatinine clearance ≥ 60 mL/min/1.73m2), then administer the full 
dose of study drug at the same intervals (valganciclovir 16 mg/kg/dose BID)  
 
If renal function is reproducibly impaired (to be confirmed by [CONTACT_114783]), then dose adjust 
as follows:  
 
CrCl 40 to 59 mL/min/1.73m2: 8 mg/kg/dose PO BID  
CrCl 25 to 39 mL/min/1.73m2: 8 mg/kg dose PO daily  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
26 
 CrCl 10 to 24 mL/min/1.73m2: 8 mg/kg dose PO every other day.  
CrCl <10 mL/min/1.73m2:  Discontinue study medication  
 
When the lab method of Scr determination is non -IDMS traceable : 
Calculation of creatinine clearance (CrCl)  30 
• Estimated CrCl (mL/min/1.73m2) = kL / Scr  
o k = proportionality constant 
o L = length (cm)  
o Scr = serum  creatinine (mg/dL)  
• k values  
o If low birth weight (< 2,500 g), during first year of life:  0.[ADDRESS_128299] year of life:  0.45 
o If ≥ 1 year of age:  0.55  
 
When the lab method of Scr determination is IDMS traceable : 
Calculation of creatinine clearance (CrCl)31 
• Estimated CrCl (mL/min/1.73m2) = kL / Scr  
o k = proportionality constant 
o L = length (cm)  
o Scr = serum creatinine (mg/dL)  
• k values  
o If low birth weight (< 2,500 g), during first year of life:  0.[ADDRESS_128300] year of life:  0.34 
o If ≥ 1 year of age:  0.41  
6.3.4.  Hepatotoxicity  
If the ALT reproducibly (within one week) increases to > 10 times above baseline, study drug 
will be held until ALT falls to < 5 times above baseline, at which time study drug will be 
restarted. If the ALT again increases 10 times above baseline, study drug will be discontinued.  In cases of drug interruption, treatment will not be prolonged beyond the originally scheduled 6 week treatment timeframe. 
6.4. Accountability Procedures for the Study 
Intervention/Investigational Product(s)  
After receipt of the study products  and supplies, the site pharmacist will dispense in an amber 
bottle that will be supplied by [CONTACT_114784] (or 
designee) or to the patient’s parent or legal  guardian.  The Principal Investigator [INVESTIGATOR_114735].   Each pharmacist will be responsible for and maintain logs of receipt, accountability, dispensation, storage conditions, and disposal of 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128301] will not be disposed of or returned until the study monitor 
reviews and confirms the drug accountability.   
• Used or partially used study product will be disposed of by [CONTACT_114785]. 
• All unopened study drug will be returned to the central drug repository from the local site pharmacy or destroyed at the site in accordance with local regulations following the direction 
from the UAB  Central Unit or its designee.  
6.5. Concomitant Medications/Treatments 
6.5.1.  Concomitant Medication Assessment  
All concomitant medications will be recorded at each study visit  throughout the treatment period 
(start of blinded study drug administration on Day 1 through Day 70. 
6.5.2.  Prohibited Therapi[INVESTIGATOR_114736]: 
 
• Cidofovir  
• Foscarnet  
• Probenecid  
• Other Investigational drugs  
 
The following concomitant medications should be used with caution: 
 
• Agents that interfere with renal function 
• Agents that interfere with bone marrow function  
• Imipenem -cilastatin  
 
The concomitant use of ganciclovir and imipenem -cilastatin has been associated with seizures, 
and this medication should only be used if the potential benefits outweigh the potential risks.  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
28 
 6.5.3.  Drug Inter actions  
In pharmacokinetic studies, the concomitant use of ganciclovir and didanosine (ddI) has been 
associated with increases in ddI concentrations of greater than 100%.  Accordingly, the possibility of increased ddI toxicity should be considered in patients receiving both medications.  
Coadministration of trimethoprim with oral ganciclovir in adults statistically significantly decreased the renal clearance of ganciclovir by 16.3%, and this was associated with a statistically significant decrease in the terminal elimination rate and corresponding increase in 
half-life by 15%. However, these changes are unlikely to be clinically significant, as the AUC0-8 
and Cmax were unaffected. The only statistically significant change in trimethoprim pharmacokinetic parameters when coadministered with ganciclovir was a 12% increase in 
Cmin. However, this is unlikely to be of clinical significance and no dose adjustment is 
recommended. 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
29 
 7. STUDY SCHEDULE  
The study procedures and evaluations are summarized in Appendix A.  Signed informed 
consent will be obtained at study enrollment and before any study -related procedures.  In 
conducting the informed consent process, the research team will adhere to the standards set 
forth by [CONTACT_114786].  Study windows are provided in parentheses 
and apply to all study events described in that subsection, unless a different window is specified 
for a particular study event. 
7.1. Enrollment  (Window: Day -90 to Day - 1) 
Following confirmation that the patient is eligible for study enrollment and obtaining informed consent, if infection with CMV has not been documented within the first [ADDRESS_128302] will be retrieved and analyzed by [CONTACT_114787]; PCR will be performed in the 
U.K. as part of routine clinical investigation protocols, while in the U.S. it will be performed at the 
UAB Central Laboratory.  If the result is positive or if there is other virologic confirmation of 
congenital CMV infection, congenital CMV is confirmed.  These subjects are eligible for 
randomization, following which the baseline assessments (see Section 7.2) will be obtained. 
Subjects who have signed the informed consent document and therefore are enrolled on the 
study but who then do not qualify for randomization in the trial (for  example, because the 
Guthrie card PCR was negative) will not be counted toward the final sample size for the study.  
Consented study participants may receive nominal compensation to offset the cost of travel, 
parking, meals, etc., for study visits in accordance with local site policies and local IRB approval.  
7.2. Randomization (Window Day -30 to Day 1) and Baseline  
(Window: Day -3 to Day 1) 
• Document congenital CMV infection 
• Obtain randomization authorization from UAB data center  
• Baseline studies will be performed following randomization of the subject on the trial  
• Document baseline demographics , selected laboratory parameters , medical history, and 
baseline conditions  (Study Day -30 to Study Day 1) (see Section 8.1.1)  
o Date of birth 
o Gender  
o Race  
o Ethnicity  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
30 
 o Birth we ight 
o Length at birth, if available 
o Head circumference at birth, if available 
o Gestational age at birth  
o Petechiae at any time from birth through study randomization, if known  
o Thrombocytopenia at any time from birth through study randomization, if obtained  
o Hepatomegaly at any time from birth through study randomization, if noted 
o Splenomegaly at any time from birth through study randomization, if noted 
o CSF white blood cell count at any time from birth through study randomization, if 
obtained  
o CSF protein concentration at any time from birth through study randomization, if 
obtained  
o CSF CMV PCR at any time from birth through study randomization, if performed  
o Seizures at any time from birth through study randomization, if noted  
o Elevated transaminases at any time from birth through study randomization, if obtained 
o Elevated bilirubin at any time from birth through study randomization, if obtained 
o Neuroimaging abnormalities, if obtained 
o Medical history and baseline conditions prior to study randomization, by [CONTACT_6764]  
o Chorioretinitis  
o Intrauterine growth restriction  
o Urine CMV testing (e.g., viral culture, shell -vial culture, PCR) within 90 days prior to 
study enrollment, if obtained clinically  
• Hematology safety labs (see Section s 6.3 and [IP_ADDRESS])  
o WBC with differential  
o Hemoglobin 
o Platelet count 
• Chemistry safety labs (see Sections 6.3 and [IP_ADDRESS]) 
o ALT 
o Total Bilirubin 
o Creatinine 
• Weight and length (see Section 8.1.2)  
• Adverse event assessment (see Section 9) 
• Concurrent medications assessment (see Section 6.6.1)  
• Obtain a new hearing assessment or record results from clinically obtained hearing 
assessment (may  be obtained any time from Study Day -90 to Study Day -1 ) (see Section 
8.1.4) 
o BSER or VRA (to assess neuro-otologic status) and OAEs (DPOAE or TEOAE) will be 
obtained.  If the BSER and/or VRA is abnormal, then bone conduction will be obtained to 
distinguish between sensorineural hearing loss, conductive loss, or mixed loss.  If the 
OAEs are abnormal, then acoustic immittance measures (tympanometry and acoustic 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
31 
 reflexes) will  be obtained to better define the middle or inner ear abnormality (e.g., otitis 
media). 
• Virology specimens for CMV viral load (see Section [IP_ADDRESS])  
• Confirm that Study Day 1 safety labs allow for dosing of study medication (see Section 6.3); 
if so, begin study medication on Study Day 1  
• Updated results of any etiological investigations for SNHL.  
7.3. Treatment (Day 1 through Day 42)  
Administer study medication twice daily  
7.4. Follow- up  
7.4.1.  Day 14 ( ± 2 days)  
• Hematology safety labs (see Sections 6.3 and [IP_ADDRESS]) 
o WBC with d ifferential  
o Hemoglobin 
o Platelet count 
• Chemistry safety labs (see Sections 6.3 and [IP_ADDRESS]) 
o ALT 
o Total Bilirubin 
o Creatinine 
• Weight and length (see Section 8.1.2)  
• Verbally assess  previous administration of study medication by [CONTACT_3654]/ guardians  
• Adjust dose of study medication for weight change, if needed 
• Adverse event assessment (see Section 9) 
• Concurrent medications assessment (see Section 6.6.1)  
• Virology specimen for CMV viral load (see Section [IP_ADDRESS])  
• Pharmacokinetic specimen for ganciclovir concentration (see Section [IP_ADDRESS])  
• Updated results of any etiological investigations for SNHL.  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
32 
 7.4.2.  Day 28 ( ± 2 days)  
• Hematology safety labs (see Sections 6.3 and [IP_ADDRESS]) 
o WBC with differential  
o Hemoglobin 
o Platelet count 
• Chemistry safety labs (see Sections 6.3 and [IP_ADDRESS]) 
o ALT 
o Total Bilirubin 
o Creatinine 
• Weight and length (see Section 8.1.2)  
• Verbally assess  previous administration of study medication by [CONTACT_3654]/ guardians  
• Adjust dose of study medication for weight change, if needed 
• Adverse event assessment (see Section 8.1.3)  
• Concurrent medications assessment (see Section 6.6.1)  
• Virology specimen for CMV viral load (see Section [IP_ADDRESS])  
• Pharmacokinetic specimen for ganciclovir concentration (see Section [IP_ADDRESS])  
• Updated results of any etiological investigations for SNHL.  
7.4.3.  Day 42 ( ± 2 days)  
• Hematology safety labs (see Section [IP_ADDRESS])  
o WBC with differential  
o Hemoglobin 
o Platelet count 
• Chemistry safety labs  (see Section [IP_ADDRESS]) 
o ALT 
o Total Bilirubin 
o Creatinine 
• Verbally assess  previous administration of study medication by [CONTACT_3654]/ guar dians  
• Discontinue study medication after Study Day 42 dosing complete 
• Adverse event assessment (see Section 9) 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
33 
 • Concurrent medications assessment (see Section 6.6.1)  
• Virology specimen for CMV viral load (see Section [IP_ADDRESS])  
• Pharmacokinetic specimen for ganciclovir concentration (see Section [IP_ADDRESS])  
• Updated results of any etiological investigations for SNHL.  
7.4.4.  Day 70 (± 4 days)  
• Hematology safety labs (see Section [IP_ADDRESS])  
o WBC with differential  
o Hemoglobin 
o Platelet count 
• Chemistry safety labs (see Section [IP_ADDRESS]) 
o ALT 
o Total Bilirubin 
o Creatinine 
• Adverse event assessment (see Section 9) 
• Concurrent medications assessment (see Section 6.6.1)  
• Virology specimen for CMV viral load (see Section [IP_ADDRESS])  
• Updated results of any etiological investigations for SNHL.  
7.4.5.  Month 4 ( ± 7 days)  
• Virology specimen for CMV viral load (see Section [IP_ADDRESS])  
• Updated results of any etiological investigations for SNHL.  
7.4.6.  Month 6 ( ± 7 days)  
• Virology specimen for CMV viral load (see Section [IP_ADDRESS])  
• Hearing assessment  (see Section 8.1.4) (to be obtained -14 days  to +30 days  from Study 
Month 6) 
o BSER or VRA (to assess neuro-otologic status) and OAEs (DPOAE or TEOAE) will be 
obtained.  If the BSER and/or VRA is abnormal, then bone conduction will be obtained to 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
34 
 distinguish between sensorineural hearing loss, conductive loss, or mixed loss.  If the 
OAEs are abnormal, then acoustic emittance measures (tympanometry and acoustic 
reflexes) will be obtained to better define the middle or inner ear abnormality (e.g., otitis 
media). 
• Updated results of any etiological investigations for SNHL.  
7.5. Final Study Visit  
At the last clinic visit, the study subject’s parent or guardian should be notified that this is the 
last contact/visit for the study.  If the family would like to know results of the study, they will be 
asked to provide contact [CONTACT_3031] (if different to information previously recorded) so that at a 
later date (after study results analyzed, the study staff can contact [CONTACT_114788]. 
7.6. Early Termination Visit  
Study subjects may withdraw voluntarily from participation in the study at any time.  Study 
subjects may also withdraw voluntarily from receiving the study intervention for any reason.  If a study subject withdraws or is discontinued from the study at any time prior to completion of the 
study , the reason for this decision will be recorded on the CRFs.  The remaining follow -up 
evaluations will be conducted if patient consent is obtained.  SAEs and AEs will be followed 
according to guidelines in Section 9.  The study subject should be encouraged to complete 
follow -up visits as part of the intent to treat group. 
Should a study subject’s therapy be discontinued prematurely, all clinical and laboratory evaluations scheduled during the next study visit will be completed on the day the study subject is discontinued.  All key endpoints will be evaluated and all randomized study subjects will 
continue to be followed as long as possible and included in the final analysis.  
7.7. Unscheduled Visit  
Should an unscheduled visit occur, it would likely be due to an adverse event.  At this visit, the study subject will be assessed as standard of care.  Recording of SAEs or AEs will be done according to Section 9.0 of this protocol . 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
35 
 8. STUDY PROCEDURES/EVALUATIONS  
The study procedures and evaluations are summarized in Appendix A.  Allowable windows for 
each study visit have been described previously.  Some assessments and medical history 
information may be collected from the subject’s medical charts as outlined below. 
8.1. Clinical Evaluations  
8.1.1.  Baseline Demographics  
To characterize the study subjects, information will be recorded at the baseline study visit (Day -
30 to Day 1, unless broader window allowed below) following the obtaining of informed consent.  
Data collected will include basic demographics  and selected laboratory parameters .  The 
following information will be collected from the subjects medical records to the extent the information is available:  date of birth; gender; race; ethnicity; birth weight; length at birth; head 
circumference at birth; and gestational  age at birth.  The degree of CMV disease involvement at 
birth will be recorded, if known, including: neuroimaging abnormalities; petechiae at any time 
from birth through study randomization; thrombocytopenia at any time from birth through study 
randomization; hepatomegaly at any time from birth through study randomization; splenomegaly at any time from birth through study randomization; CSF white blood cell count at any time from 
birth through study randomization; CSF protein concentration at any time from  birth through 
study randomization; CSF CMV PCR at any time from birth through study randomization; 
seizures at any time from birth through study randomization; elevated transaminases at any time from birth through study randomization; elevated bilirubin at any time from birth through 
study randomization.   Medical history and baseline conditions prior to study randomization will 
be recorded by [CONTACT_6764] . 
8.1.2.  Growth  
To adjust study medication for weight gain, weight will be recorded at multiple study v isits.  To 
assess renal function, length will be recorded at multiple study visits for use in calculating creatinine clearance.  
8.1.3.  Adverse Event Assessment  
At each study visit from the receipt of first dose of study drug and continuing through four  weeks 
following the final dose of study drug, the study subject will be assessed for any adverse events 
(see Section 9). 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
36 
 8.1.4.  Hearing Assessment  
At the study visits on Week 0  (window: Study Day -90 to Study Day -1) and Month 6 (window: -
14 days  to +30 day s), age-appropriate assessments of hearing will be performed.  Results of 
hearing assessments conducted for clinical care may be utilized if conducted within the study 
window. BSER and/or visual reinforcement audiometry (VRA) (to assess neuro-otologic status) 
and OAEs (DPOAE or TEOAE) will be obtained.  If the BSER and/or VRA is abnormal, then 
bone conduction will be obtained to distinguish between sensorineural hearing loss, conductive 
loss, or mixed loss.  If the OAEs are abnormal, then acoustic i mmittanc e measures 
(tympanometry and acoustic reflexes) will be obtained to better define the middle or inner ear 
abnormality (e.g., otitis media). 
If a study subject proceeds to cochlear implantation during the course of the study, he/she will 
not require additional study -related hearing assessments following the implantation procedure.  
Prior to the implantation, efforts will be made to obtain audiology testing that would have been 
performed at the Month 6 visit.  
8.2. Laboratory Evaluations 
Blood for study -specified laboratory evaluations may be obtained by [CONTACT_114789]:  veni puncture, heel stick, indwelling heparin- or saline-locked intravenous catheter, 
etc.  As detailed below, blood will be obtained for assessment of hematology safety labs, chemistry safety labs, whole blood CMV viral load/resistance testing, and ganciclovir population 
pharmacokinetics.  If an insufficient volume of blood is obtained for all of the tests at any given study visit, the following prioritization as to which tests to send will apply (most important to least 
important):  1) hematology safety labs (most important); 2) chemistry safety labs (second most important); 3) whole blood CMV viral load/resistance testing (third most important); and 4) ganciclovir population pharmacokinetics (least important).  With the exception of the hematology safety labs and the creatinine and ALT assessments, those lab tests which are unable to be 
obtained due to lack of sufficient blood or parental refusal  at a given study visit will not be 
reported as protocol deviations.  If urine is not obtainable, a protocol deviation will not be 
reported. Saliva will be collected using polyester fiber– tipped swabs.  As far as possible safety 
labs and other research specimens should be taken to coincide with clinical care.  If it is not possible to obtain samples for safety labs at a study visit and bloods were obtained for clinical care within [ADDRESS_128303] during the period of valganciclovir administration, and an 
additional  3.0 mL will be drawn for study labs when valganciclovir is not being administered.  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
37 
 The breakdowns of the amount of blood for individual tests are provided in Appendix A, and 
below.  Clinical laboratory results can be used  for chemistry and hematology safety labs if 
collected for clinical care and within the required study window.  If labs drawn for the study 
required assessments are not evaluable, blood draws will not be repeated. 
[IP_ADDRESS].  Hematology Safety Labs 
All hematology safety laboratory assessments will be conducted at the PI’s local lab.  These 
assessments  will provide information on the safety of administering the study drug.  They will be 
collected at each study visit while the study subject is receiving valganciclovir and at the two 
week visit thereafter.  The following will be tested:  white blood cell count, differential, hemoglobin, and platelet count.  The total amount of blood required for the hematology safety 
labs is 2.5 mL over 8 weeks . 
[IP_ADDRESS].  Chemistry Safety Labs 
All chemistry safety laboratory assessments will be conducted at the PI’s local lab.  These 
assessments will provide information on the safety of administering the study drug.  They will be collected at each study visit while the study subject is receiving valganciclovir and at the two 
week visit thereafter.  The following will be tested:  ALT, total bilirubin, and creatinine.  The total amount of blood required for the chemistry safety labs is 5.0 mL over 8 weeks . 
8.2.2.  Special Assays or Procedures  
[IP_ADDRESS]. CMV Viral Load/Resistance Testing 
Assessment of CMV viral load in whole blood will be conducted at the UAB  Central Laboratory.  
In study subjects with increasing whole blood viral loads during the course of treatment, assessment for antiviral resistance may be undertaken on the serially collected samples.  Whole blood will be collected at each study visit.  The total amount of blood required for the whole 
blood CMV viral loads is 3.5 mL over 6 months .  CMV viral load will be assessed by [CONTACT_114766].  
Urine collection by [CONTACT_114790].  If 
urine is not obtainable, a protocol deviation will not be reported. Saliva will be collected at each 
study visit.  Specimens will be shipped to the UAB  Central Laboratory for analysis.  
Antiviral resistance will be performed in the UAB Viral Resistance Labor atory. 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
38 
 [IP_ADDRESS]. Ganciclovir Population Pharmacokinetics 
Assessment of ganciclovir plasma concentrations will be conducted at the UAB Central 
Pharmacokinetic Laboratory.  Ganciclovir concentrations will be obtained with each blood draw 
obtained while the subject is receiving valganciclovir  (Study Day 14, Study Day 28, and Study 
Day 42).  Assessments on each of the Study Days will consist of a single trough specimen.  For each subject, one of these three draws will occur [ADDRESS_128304] 200 µ L (0.2 mL).  Specimens will be processed to separate the 
plasma, which will be shipped to the UAB Central Pharmacokinetic Laboratory. 
8.2.3.  Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007] 
[IP_ADDRESS]. Instructions for Specimen Preparation, Handling, and Storage 
Specific instructions on specimen collection, preparation, handling, and storage will be provided 
in the Manual of Procedures for this study.  
[IP_ADDRESS]. Specimen Shipment 
Specific instructions on specimen shippi[INVESTIGATOR_114737].  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
39 
 9. DMID SAFETY REPORTING AND SAFETY MONITORING 
Regulatory requirements including the Food and Drug Administration (FDA) regulations, 
International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice (GCP), 
and European Union (EU) Clinical Trials Directive set forth safety monitoring and reporting responsibilities of sponsors and
 investigators to ensure the safety and protection of human 
subjects participating in clinical trials. 
9.1. Responsibilities  
Investigators participating in this clinical trial are responsible for and will: 
• Evaluate subject safety including assessment of adverse events (AEs) for 
seriousness, severity, and causality;  
• Notify the Central Unit (the Central Unit notifies the sponsor, DMID), of protocol -
defined serious adverse events (SAEs) within 24 hours; (details provided in the 
MOP)  
• Provide detailed written reports, including necessary documentation requested by [CONTACT_114791] (IRB)/independent ethics committee (IEC), 
promptly following immediate initial reports; and  
• Inform the IRB/IEC of AEs as required by [CONTACT_25435]. 
9.2. Adverse Event (AE) 
9.2.1.  Definition of an Adverse Event  
 Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporally associated with the use of medicinal (investigational) product whether or not 
considered drug related. The occurrence of an AE may come to the attention of study personnel 
during study visits and interviews of a study recipi[INVESTIGATOR_12189], or upon review by a study monitor.  
9.2.2.  Documentation of Reportable Adverse Events 
Information to be collected on reportable AEs includes event description, time of onset, clinician’s  assessment of severity, relationship to study product (assessed only by [CONTACT_114792] e a diagnosis, which would include MD or DO), and time of 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
40 
 resolution/stabilization of the event. All AEs occurring from Study Day [ADDRESS_128305] be documented appropriately regardless of 
relationship. All AEs will be followed to adequate resolution. SAE reporting is described in section 9.5.  
Any medical condition that is present at the time that the patient is randomized should be 
considered as a baseline condition and not reported as an AE. However, if the e vent meets the 
criteria in Section 9.2.1 and the grade of the event worsens at any time during the study, it 
should be recorded as an AE
. 
9.3. Investigator’s Assessment of Adverse Event 
The determination of seriousness, severity, and causality will be made by [CONTACT_63689]-site investigator who is qualified (licensed) to diagnose AE information, provide a medical evaluation of AEs, and classify AEs based upon medical judgment. This includes MD or DO.  Events will be identified 
by [CONTACT_114793].  If a subject is hospi[INVESTIGATOR_057], the medical record should be 
reviewed to identify AEs.  The PI [INVESTIGATOR_114738].  
9.3.1.  Assessment of Seriousness  
Event seriousness will be determined according to the protocol definition of an SAE (see Section 9.5).  
9.3.2.  Assessment of Severity  
All reportable AEs will be graded according to the DIADS Toxicity Table (Appendi x B).   
9.3.3.  Assessment of Relationship to Study Product  
Relationship to Study Products:  The clinician’s assessment of an AE's relationship to valganciclovir study drug  is part of the documentation process, but it is not a factor in 
determining what is or is not reported in the study.  If there is any doubt as to whether a clinical 
observation is an AE, the event should be reported. All AEs must have their relationship to study 
product assessed using the terms: related or not related. In a clinical trial, the study product must always be suspect.  
The investigator must provide an assessment of relationship of AEs to the study product based 
on: 
• Temporal relationship of the event to the administration of study product;  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
41 
 • Whether an alternative etiology has been identified; 
• Biological plausibility; and 
• Existing therapy, and/or concomitant medications .  
To help assess, the following guidelines are used: 
• Related– There is a reasonable possibility that the study product caused the adverse 
event. Reasonable possibility means that there is evidence to suggest a causal 
relationship between the study product and the adverse even t. 
• Not Related– There is not a reasonable possibility that the administration of the 
study product caused the event.  
9.4. Study Related  Adverse Events 
In earlier investigations of ganciclovir and valganciclovir in infants, the side effect that was seen 
commonly  was neutropenia.  Therefore, neutropenia occurring during the course of the 
treatment period of the study will be assumed to be associated with study medication. 
• The study drug related and expected adverse events as documented from prior studies 
consist of: 
o anemia 
o neutropenia  
o diarrhea, and 
o elevated alanine aminotransferase (ALT) . 
9.5. Serious Adverse Event (SAE)  
9.5.1.  Definition of a Serious Adverse Event  
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either the investigator or sponsor, it results in any of the following outcomes:  
• Death, 
•  a life-threatening adverse event*,  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
42 
 • inpatient hospi[INVESTIGATOR_1081],  
• a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or  
• a congenital anomaly/birth defect.   
• Important medical events that may not result in death, be life- threatening, or require 
hospi[INVESTIGATOR_12190], based upon appropriate medical judgment they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
* Life-threatening adverse event. An adverse event is considered “life-threatening” if, in the view 
of either the investigator or sponsor, its occurrence places the patient or subject at immediate risk of death.  It does not include an adverse event that, had it occurred in a more severe form, 
might have caused death.
 
Events related to cochlear implantation will  be recorded on the CRF, but will not be considered 
an AE or SAE unless meeting one or more of the above outcomes: 
All SAEs will be:  
• recorded on the appropriate SAE e CRF 
• followed through resolution or stabilization by a study clinician 
• reviewed and evaluated by a study clinician  
9.5.2.  Reporting Interval  
Document all AEs and SAEs from Study Day [ADDRESS_128306], the investigator will report the event. 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128307] 
be made to the Clinical Studies  Administrator at the Central Unit.  Within 24 hours of 
identification, the SAE will be entered into the eCRF and the original signed SAE document will 
be faxed to the Central Unit.  If a signature [CONTACT_114842] [INVESTIGATOR_114739] 24 hours, it will be 
faxed without the signature.   
Fax: 205-935 -8559 to the attention of Central Unit Safety Coordinator . 
 The Central Unit will report all serious adverse events to DMID pharmacovigilance contractor, at 
the following email address:  SAE Email address - [EMAIL_1393]
. 
 
Should it be necessary for the Central Unit to contact [CONTACT_114794]: 
 
DMID Pharmacovigilance Group 
Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_128308]., Suite 650 
Bethesda, MD [ZIP_CODE], [LOCATION_003]  
SAE Hot Line: [PHONE_2618] (US) or [PHONE_2619] (outside US)  
SAE FAX Phone Number: [PHONE_2620] (US) or [PHONE_2621] (outside US)  
Other supporting documentation of the event may be requested by [CONTACT_114795].  The DMID pharmacovigilance 
contractor will notify the DMID medical monitor and clinical protocol manager. The DMID 
medical monitor will review and assess the SAE for regulatory reporting and potential impact on study subject safety and protocol conduct. At any time after completion of the study, if the 
investigator becomes aware of an SAE that is suspected to be related to study product, the 
investigator will report the event to the DMID Pharmacovigilance Group. 
9.5.4.  Regulatory Reporting for Studies Conducted Under DMID -Sponsored 
IND 
Following notification from the Central Unit   DMID, the IND sponsor, will report to FDA any suspected adverse reaction that is both serious and unexpected.  DMID will report an adverse 
event as a suspected adverse reaction only if there is evidence to suggest a causal relationship 
between the drug and the adverse event.  DMID will notify FDA and all participating investigators (i.e., all  investigators to whom the sponsor is providing drug under its INDs or 
under any investigator’s IND) and the Central Unit in an IND safety report of potential serious risks from clinical trials or any other source, as soon as possible, but in no case later  than 15 
calendar days after the sponsor determines that the information qualifies for reporting as 
specified in 21 CFR Part 312.32. DMID will also notify FDA of any unexpected fatal or life-
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
44 
 threatening suspected adverse reaction as soon as possible but in no case later than 7 calendar 
days after the sponsor’s initial receipt of the information.  Relevant follow -up information to an 
IND safety report will be submitted as soon as the information is available. Upon request from 
FDA, DMID will submit to FDA any additional data or information that the agency deems 
necessary, as soon as possible, but in no case later than [ADDRESS_128309].  
All serious events designated as “not related” to study product(s), will be reported by [CONTACT_114796] a summary format.   
The Site Investigator is responsible for informing the Ethics Committee and/or IRB of the SAE 
as per local requirements.  For non- US sites, the site investigator is responsible for also 
informing their Regulatory Authority as required by [CONTACT_114797]. 
9.6. Halting Rules  
9.6.1.  Discontinuation of Study participation for individual subject  
Subjects with neutropenia, thrombocytopenia, renal impairment, or hepatotoxicity will be discontinued from study treatment if the criteria outlined in Section 6.[ADDRESS_128310] been constructed to interrupt study enrollment if an excessive number of subjects are experiencing neutropenia.  In the CASG 102 study, 63% of subjects receiving parenteral ganciclovir developed Grade 3 or Grade 4 neutropenia.
20  In the CASG 109 
study, 38% of subjects receiving oral valganciclovir developed Grade 3 or Grade 4 neutropenia.
24  Whether this lower rate of neutropenia relates to the mode of drug delivery is not 
known at this time.  Assuming that 75% of subjects receiving ganciclovir developed Grade 3 or 
4 neutropenia and given that randomization is expected to be balanced between those in study 
drug and those in placebo, the stoppi[INVESTIGATOR_114740] (i.e., placebo and active subjects combined) is 37.5%.  Therefore, study enrollment will be stopped and an ad hoc review will be performed if a significantly higher 
proportion ( 37.5%) of subjects in this study experience Grade 3 or Grade 4 neutropenia, as 
detailed in the following table: 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128311] to 0.05.  
 
Number 
enrolled (Y)  Stop/Investigate 
when number with 
events equals this 
number (X)  Probability of 
observing X or  
more events 
assuming 
p=0.375   Number 
enrolled (Y)  Stop/Investigate when 
number with events 
equals this number (X)  Probability of 
observing X or 
more events 
assuming 
p=0.375  
4 4 0.020   30 17 0.025  
5 5 0.007   31 17 0.037  
6 5 0.031   32 18 0.024  
7 6 0.013   33 18 0.034  
8 6 0.036   34 18 0.048  
9 7 0.017   35 19 0.032  
10 7 0.038   36 19 0.044  
11 8 0.019   37 20 0.030  
12 8 0.039   38 20 0.041  
13 9 0.021   39 21 0.028  
14 9 0.039   40 21 0.038  
15 10 0.021   41 22 0.026  
16 10 0.037   42 22 0.035  
17 11 0.021   43 22 0.047  
18 11 0.036   44 23 0.032  
19 12 0.021   45 23 0.043  
20 12 0.034   46 24 0.030  
21 13 0.020   47 24 0.040  
22 13 0.033   48 25 0.028  
23 13 0.050   49 25 0.037  
24 14 0.031   50 25 0.048  
25 14 0.046   51 26 0.034  
26 15 0.029   52 26 0.044  
27 15 0.043   53 27 0.032  
28 16 0.027   54 27 0.041  
29 16 0.040      
Additionally, DMID and the Central Unit may interrupt study dosing and/or study entry at any time if medically indicated.  To minimize risk, the medical monitor and the DSMB will review cumulative safety data.  If enrollment is halted based upon the table above or the review of the 
safety data, upon completion of the rev iew and receipt of advice of the DSMB, DMID and the 
Central Unit Administration will determine if study entry or study dosing may continue according 
to the protocol. 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128312] with the study and will be selected by [CONTACT_18121].  The initial responsibility of the DSMB will be to review and make recommendations regarding the initiation of the study. A simple majority will be considered a DSMB quorum for voting and meeting purposes.  
Members will be able to submit data review comments electronically if they are not able to 
participate in a data review meeting teleconference.  After the initiation of the study and during the course of the study at intervals determined by [CONTACT_114798], the DSMB will:  
 1. Review the research protocol, template informed consent document and plans for data and 
safety monitoring. 
2. Evaluate the progress of the study, including periodic assessments of data quality and 
timeliness, participant recruitment, accrual and retention, participant risk versus benefit, performance of the trial sites, and other factors that can affect study outcome. 
3. Review study endpoints for differences between groups and to assess if  
SAEs are occurring at a rate greater than expected. 
4. Consider factors external to the study when relevant information becomes available,  
5. Monitor the confidentiality of the study data and the results of monitoring.  
  The S&DCC will provide all data, tables, unique and repeated listings, figures, descriptive statistics, and tests of significance requested by [CONTACT_114799], interim analysis 
plan and final analysis.  
 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128313] protection, study procedures, 
laboratory procedures, study intervention administration, and data collection processes are of 
high quality and meet sponsor, GCP/ICH, and regulatory guidelines, and that the stu dy is 
conducted in accordance with the protocol and study manuals.  NIAID/ DMID, the sponsor of 
this study, or its designee will conduct site monitoring visits as detailed in the monitoring plan.  
Site visits will be made at standard intervals in accordance with the monitoring plan.  More 
frequent visits may be made if needed.  Monitoring visits will include, but are not limited to, review of regulatory files, case report forms, informed consent forms, medical and laboratory reports, and protocol compliance.  Study monitors will meet with investigators to discuss any 
problems and actions to be taken and document visit findings and discussions.  
Every effort will be made to maintain the anonymity and confidentiality of subjects during this 
study.  However, because of the experimental nature of this treatment, the Investigator agrees 
to allow representatives of the Sponsor (DMID/NIAID)  as well as authorized representatives of 
the Food and Drug Administration or other Regulatory agencies, Genentech/[COMPANY_002], or the UAB 
Central Unit, to inspect the facilities used in this study and to inspect, for purposes of 
verification, the hospi[INVESTIGATOR_114741] .  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128314] developed CMV -associated hearing loss.  This study is designed as a proof 
of principle study.  
11.2.  Sample Size Considerations 
Subjects will be randomized 1:1 to valganciclovir  oral solution or valganciclovir placebo.  A 
sample size of 54 (27 in each arm)  has 90 % power to detect a worsening of hearing from 40% 
to 8.0% in the treatment group based on analyzing two correlated binary outcomes with 
correlation coefficient of 0.55 at 2.5% level of significance (using PASS 2008 program).  
Randomization will be stratified by [CONTACT_81450] (1 through 11 months, 12 through 23 
months, 24 through 35 months, and ≥ 36 months ) and by [CONTACT_114800] (symptomatic and 
asymptomatic at birth) as a marker of disease severity . 
Efficacy and safety analysis will be based on intent-to-treat population (ITT), defined as  any 
child who receives at least one dose of study medication and who has complete hearing 
assessment data at baseline and Month 6.  Children who completed the full six weeks of study 
medication and have hearing assessment data at baseline and Month 6 will be included in a per 
protocol (PP) analysis of efficacy, which will be performed as a sensitivity analysis .  Since the 
primary endpoint requires comparison of baseline and 6 month audiology assessments, 
dropouts and subjects with audiology assessments that are inadequate for study comparison 
will be replaced. 
11.3.  Planned Interim Analyses (if applicable) 
No interim analysis for futility or efficacy is proposed because this is a small sample study and 
the penalty for an early look at the outcome data would compromise the study.  However, a 
safety review will be done periodically.  
11.3.1.  Safety Review  
Safety reports will be generated and sent to DMID to be diss eminated to the DSMB. This report 
includes hematology and safety laboratory values and adverse events (serious and non-
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
49 
 serious).  In addition, Section 9.7 provides a table of halting rules based on the number of 
subjects experiencing Grade 3 or 4 neutropenia for consideration by [CONTACT_4318].  
11.3.2.  Immunogenicity or Efficacy Review  
None.  
11.4.  Final Analysis Plan  
11.4.1.  Primary Outcome 
Primary analysis will be based on intent-to-treat population. Categories utilized for hearing 
assessment of each ear for each time point are normal hearing, mild hearing loss, moderate 
hearing loss, and severe hearing loss. Based on the hearing assessment of each ear at Month 6 
and at Baseline, change in each ear will be categorized into binary outcomes : improved + no 
change versus other (i.e., worsened).  For example, normal in the left ear at baseline and 
moderate in the same ear at Month 6 will be considered as worsened. The primary outcome will 
be analyzed using logistic regression based on generalized estimating equations (GEE) in order 
to accommodate the correlation between the left and right ears of a subject in the modeling. In 
addition, if there are enough data available we will adjust the analyses by [CONTACT_114801] a 
subject at birth is asymptomatic or symptomatic from their congenital CMV infection. Additional 
analyses will be performed to adjust for age and site plus any imbalances in the demographic and clinical characteristics to determine if adding them to the model will impact the results. P-
values < 0.[ADDRESS_128315] who is masked (blinded) to treatment assignment will assess the audiology test battery for each subject and assign the classifications of normal 
hearing, mild hearing loss, moderate hearing loss, or severe hearing loss based upon their 
hearing thresholds (in decibels). The classifications will be assigned by [CONTACT_39596] (one for the left ear and one for the right ear), giving “total ear” classifications.  Following this, the study audiologist 
will assign the “best ear” classification for the subject at that study visit; for example, if a subject 
had mild hearing loss in their left ear and severe hearing loss in their right ear, then the “best ear” classification will be mild hearing loss.  
Prima ry analyses will be done on the first 54 subjects recruited.  If there were subjects enrolled 
as replacement for dropouts or missing outcome, these added subjects will be included in the secondary analyses.  
For those with missing outcome due to missing baseline and/or Month 6 audiology  (including 
dropouts) , we will exclude them from the primary analysis. However, we will  perform  sensitivity 
analysis by [CONTACT_114802] “worsening” outcome.” 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128316] ear will be categorized into binary 
outcomes – namely:  1) i mproved + no change versus others, which examines positive hearing 
outcomes defined as improved hearing or protection from hearing impairment in subjects who started with normal hearing at baseline; 2) worsened versus others, which examines 
deterioration or worsening of hearing; 3) i mproved versus o thers; and 4) worse + n o change 
versus o thers .  Similar analyses will be performed for total ears (worsened versus o thers, 
improved versus others, and worse + no change versus others. 
For other secondary and tertiary outcomes, Fisher’s exact test will be used to compare binary 
outcomes (such as detection of viruria or subject with at least one AE or SAE), and Wilcoxon 
Rank test will be used to compare continuous outcomes  (such as quantitative log reduction) 
between the two treatment groups 6 weeks and 6 months after initial treatment. 
Logistic model utilizing generalized estimating equations will also be used to determine the 
association between change in hearing and change in viral load. Change in viral load over time will be measured by [CONTACT_114803]. Spearman 
rank correlation will be utilized to examine the association between viral load and PK 
parameters. Poisson regression model will be used to compa re the number of AEs/SAEs 
experienced by [CONTACT_114804]. 
As in the primary outcomes, missing change in hearing outcomes will be replaced by [CONTACT_114805]..  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
51 
 12. SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  
The site will maintain appropriate medical  and research records for this trial, in compliance with 
ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of 
confidentiality of subjects. As part of participating, the site will permit authorized representatives of the sponsor(s), DMID, the UAB Central Unit and regulatory agencies to examine (and when required by [CONTACT_1289], to copy) clinical records for the purposes of quality assurance 
reviews, audits, and evaluation of the study safety and progress.  
Documentation of source data is necessary for the reconstruction, evaluation, and validation of 
clinical findings, observations, and other activities during a clinical trial.  Source data are all 
information, original records of clinical findings, observations, or other activities in a clinical trial 
necessary for the reconstruction and evaluation of the trial.  Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office 
charts, laboratory notes, memoranda, subjects’ evaluation checklists, pharmacy dispensing 
records, recorded data from automated instruments, Source Document Worksheets (SDWs), copi[INVESTIGATOR_10379], microfiches, 
photographic negatives, microfilm or magnetic media, x -rays, and subject files and records kept 
at the pharmacy, at the laboratories, and medico-technical departments involved in the clinical 
trial.  Source documentation serves to substantiate the integrity of trial data, c onfirms 
observations that are recorded, and confirm the existence of study participants.  This standard also serves to ensure data quality by [CONTACT_114806], complete, and accurate.  Sites that are participating in this trial should consult the 
MOP, and DMID/NIAID Source Document Standards (most current version) for specific 
instruction and forms. 
Local, state, institution, IRB/independent ethics committee (IEC) policies and procedures may 
be different from those stated in this standard.  The site should refer to local, state, institution, 
IRB/IEC policies and procedures and follow them if they are more stringent than the DMID Standards. 
According to the ICH GCP 4.9: “The investigator should ensure the accuracy, completeness, 
legibility, and timeliness of the data reported to the sponsor in the eCRFs and in all required 
reports.  Data reported on the eCRFs, which are derived from source documents, should be consistent with the source documents or discrepancies should be explained.”  
SDWs that mirror each data field on the eCRF will be available for use by [CONTACT_114807].  Some data on the SDW may be extracted from the medical record or other source documents, and some data may be recorded 
on the SDW as the source document. 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128317] a quality management plan.  Data will be evaluated for compliance with 
the protocol and accuracy in relation to source documents.  The study will be conducted in 
accordance with procedures identified in the protocol.  Items to be reviewed include, but are not 
limited to: eligibility (including informed consent), AE reporting, study/clinical endpoints, follow -
up contacts, regulatory documents, study discontinuation, and review of clinical records.  Data 
that will be reviewed, who is responsible for implementation, and the schedule for internal reviews will be specified or referenced in the quality management plan.   
 
The investigational sites are responsible for conducting routine quality control (QC) and quality assurance (QA) activities to internally monitor study progress and protocol compliance.  The Principal Investigators will provide direct access to all tri al-related sites, source data /source 
documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_3482]. The Principal Investigator [INVESTIGATOR_92201].   
DMID clinical site monitors will verify the clinical trial is conducted and data are generated, documented (recorded), and reported in compliance with the protocol, Good Clinical Practice, and the applicable regulatory requirements.  Clinical monitoring reports will be submitted to 
DMID  and to the Central Unit.. The Statistical and Data Coordinating Center (SDCC) will 
implement quality control procedures beginning with the data entry system and generate data 
quality control checks that will be run on the database.  Missing data or data anomalies will be 
communicated to the site(s) for clarification and resolution by [CONTACT_114808]. 
 The  study monitors will verify that the clinical trial is conducted and data are generated, 
documented, and reported in compliance with the protocol, ICH E6(R1), and the applicable regulatory requirements.  Reports will be submitted to DMID on monitoring activities.  The study site will provide direct access to all trial -related sites, source data/documents, and reports for 
the purpose of monitoring and auditing by [CONTACT_114809].  
The Statis tical and Data Coordinating Center ( S&DCC) has extensive experience in data 
management for over approximately 16 currently active national/international collaborative 
studies, and systems and approaches employed for this proposal will be based on existing, highly successful platforms.  A distributed data management system, where the clinical 
centers are responsible for the entry and management of data from their own center, is both 
cost-effective (as it removes a significant number of queries) and result s in higher quality 
data.
 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
53 
 14. ETHICS/PROTECTION OF HUMAN SUBJECTS  
14.1.  Ethical Standard  
This trial will be conducted in compliance with the protocol, International Conference on 
Harmonization Good Clinical Practice E6 (ICH -GCP), and the applicable regulatory 
requirements, including:  
• U.S. Code of Federal Regulations applicable to clinical studies (45 CFR 46 and 21 CFR including parts 50 and 56 concerning informed consent and IRB regulations, if under IND, 21 CFR 312). 
• Completion of Human Subjects Protection Training.  Refer to 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD -01-061.html
; 
http://cme.cancer.gov/clinicaltrials/learning/humanparticipant-protections.asp  
The investigator will ensure that this study is conducted in full conformity with the principles set 
forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research of the US National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6; 62 Federal Regulations [ZIP_CODE] (1997). 
14.2.  Institutional Review Board  
Reviewing IRBs must be registered with the OHRP to conduct FDA -regulated studies.  In the 
[LOCATION_002] and in other countries, institutions are required to hold a current US Federalwide 
Assurance (FWA) issued by [CONTACT_114810].  
 
This protocol, informed consent documents, relevant supporting information, and all types of 
volunteer recruitment or advertisement information will be submitted to the Institutional Review Board (IRB) for review and must be approved before the study is initiated.  Any amendments to 
the protocol must also be approved by [CONTACT_114811].  
 
The investigator is responsible for keepi[INVESTIGATOR_114742], but in any case at least once per 
year.  The investigator must also keep the IRB informed of any significant AEs. 
All IRB  approved documents as well as relevant study correspondence should be copi[INVESTIGATOR_114743].  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128318] be documented in the medical records, clinic 
chart, and/or research chart.  The consent form must be signed and dated by [CONTACT_114812]/study participant’s parent/legal guardian before participation in the study.  A copy of 
the signed consent form must be provided to the study participant/study participant’s parent/legal guardian.  Signed consent forms must remain in each study participants study file 
and must be available for verification by [CONTACT_9534].  
 The investigational nature and research objectives of this trial, the procedure, and its attendant 
risks and discomforts will be carefully explained to the study participant/study participant’s 
parent/legal guardian.  A signed informed consent document will be obtained from each study participant/study participant’s parent/legal guardian prior to entry into this study.  At any time 
during participation in the protocol, if new information becomes available relating to risks, AEs, 
or toxicities, this information will be provided orally or in writing to all enrolled or prospective study participant/study participants’ parent/legal guardian. Documentation will be provided to the IRB and, if necessary, the informed consent will be amended to reflect any relevant information. 
An investigator shall seek such consent only under circumstances that provide the prospective 
subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence. The information that is given to the subject or the representative shall be in language understandable to the subject or the 
representative. 
Subjects/subject’s parent/legal guardian will sign the informed consent document prior to any 
procedures being done specifically for the study.  Subjects/subject’s parent/legal guardian should have the opportunity to discuss the study with their family, friends or personal physician, 
or think about it prior to agreeing to participate.  Subjects/subject’s parent/legal guardian may 
withdraw consent at any time throughout the course of the trial.  A copy of the informed consent document will be given to the subjects /subject’s parent/legal guardian for their records.  The 
rights and welfare of the subjects will be protected by [CONTACT_114813]. 
14.3.1.  Informed Consent/Assent Process (in Case of a Minor)  
Not applicable. 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
55 
 14.4.  Exclusion of Women, Minorities, and Children (Special 
Populations)  
This pediatric study will not exclude young children, females, or minorities.  This study will be 
inclusive of all children who meet the inclusion/exclusion criteria, regardless of religion, gender, 
or ethnic background.  
14.5.  Subject Confidentiality  
The information obtained during the conduct of this clinical study is confidential, and disclosure 
to third parties other than those noted below is prohibited.  The results of the research study 
may be published, but study participant’s names or identities will not be revealed.  Records will remain confidential.  To maintain confidentiality, the principal investigators at each site will keep 
records in locked cabinets and the results of tests will be coded to prevent association with 
volunteers’ names.  Data entered into computerized files will be accessible only by [CONTACT_114814].  Data received by [CONTACT_114815]/[COMPANY_002] will not include subject specific data but only encoded data.  
However, subject specific information will be available to the clinical monitors, to the FDA and to 
health authorities where provided by [CONTACT_2371].  The NIAID/DMID, Genentech/[COMPANY_002], and the UAB 
Central Unit may use information obtained during the conduct of this study in connection with 
the development of the study drug.   
 The study investigator is obliged to provide the Sponsor (DMID/NIAID)  and the S&DCC with 
complete test results and all data developed in this study.  The Sponsor may disclose this 
information to appropriate regulatory authorities as deemed necessary. .   
  
Subject-speci fic information may be provided to other appropriate medical personnel only with 
the study participant’s permission.  To ensure compliance with current ICH guidelines, data 
generated by [CONTACT_114816], the Sponsor, UAB Central Unit, and/or the IRB/IEC for 
each study site.  
14.6.  Study Discontinuation  
Please see S ection 5.3 for criteria for discontinuing study and / or study subject participation.  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
56 
 14.7.  Future Use of Sto red Specimens  
Some of the specimens obtained from study participants during this study will be stored 
indefinitely in the Children’s Diagnostic Virology Laboratory  at the University of Alabama at 
Birmingham and may be used in future CMV research.  These specimens will be labeled with a code number and not with the study participant’s name.  At the time of consent for study participation, study participant’s parent/legal guardian will have the opportunity to either agree to 
have their specimens used in future CMV research or decline to have their specimens used in 
future CMV research.  The study participant’s parent/legal guardian will indicate his/her preference by [CONTACT_114817], “Future Use of Specimens”.  Non-protocol designated, future testing of 
samples will be performed only on samples from study participants who have consented for future testing of samples.  These specimens will only be utilized to better under stand the natural 
history of CMV or improve diagnosis. 
A repository for residual samples will be established according to OHRP guidelines ensuring 
that codes or other personally identifying links will not be distributed to future researchers. 
If the study participant’s parent/legal guardian has indicated in the signed consent form that 
he/she does not agree to allow the future use of specimens for future CMV research, then 
his/her child’s specimens will be destroyed at the completion of the study. 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128319] KEEPI[INVESTIGATOR_114744], completeness, legibility, and timeliness 
of the data reported. 
Electronic case report forms (eCRFs) will be developed by [CONTACT_114818].  The eCRFs will be provided electronically by [CONTACT_114819].  
Original data will be recorded on source documents (e.g., medical records, research progress 
notes, Source Document Worksheets documenting research related procedures).  Source Document Worksheets that contain each data field on the eCRF will be available for use by 
[CONTACT_1203] a tool to record and maintain data for each study participant enrolled in the study when 
other source documents are not used to collect original data.  All source documents  should be 
completed in a neat, legible manner to ensure accurate interpretation of data.  When making a change or correction, cross out the original entry with a single line and initial and date the 
change.  DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE 
ORIGINAL.  Specific guidance to investigators and study staff on making corrections to source documents and eCRFs will be provided in the MOP for this study.  
Data recorded on the eCRF that differ from source documents must be explained on the Add 
Comment eCRF and in the subject’s source documents.  With the exception of calculation(s)/conversion(s) of data values, all calculation(s)/conversion(s) must be shown in the 
source documents for verification.  
The integrity of the data is ensured by [CONTACT_114820].  Each person (at 
study sites, the UAB Central Unit, and the DCC) is assigned access to only the portions of the 
database they need.  Each person’s access is provided under “hard” password protection (at 
least 8 characters and including both symbols and numbers) that are changed at [ADDRESS_128320] be reviewed by [CONTACT_093]’s research team, under the supervision of the investigator, who will ensure that they are accurate and complete.  All data must be supported by [CONTACT_18412], which will remain available for review by [CONTACT_114821].  Adverse events must be graded, assessed for intensity and causality, and reviewed 
by [CONTACT_114822].  All laboratory values must be assessed for clinical significance and non clinical significance, and reviewed by [CONTACT_114822].  Sites that are participating in this trial should consult the MOP and DMID/NIAID Source 
Document Standards (most current version) for specific instruction.      
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128321] maintain complete and accurate 
documentation for the study.   
The UAB Central Unit and Statistical and Data Coordinating  will be responsible for data 
management, quality review, analysis of the study data, and writing of the clinical study report.  
15.2.  Data Capture Methods 
Clinical and laboratory data will be entered into a 21 CRF Part 11 compliant Internet Data Entry 
System (IDES)  provided by [CONTACT_114823].  The data system includes password protection and internal quality checks, such as automated range 
checks, to identify data that appear to be inconsistent, incomplete, or inaccurate. 
15.3.  Types of Data 
Data for this study will include safety, laboratory (e.g., clinical and virologic), and outcome 
measures (e.g., virology, audiology).  
15.4.  Timing/Reports  
Safety Reports will be generated and sent to DMID at intervals identified in the DSMB Charter, 
for dissemination to the DSMB.  
15.5.  Study Records Retention  
Records and documents pertaining to the conduct of this study, including source documents, 
consent forms, laboratory test results, and medication inventory records, must be retained by 
[CONTACT_114824] 2 years following completion of the study.  No study records shall be destroyed without prior authorization from the UAB Central Unit and NIAID/DMID.  These documents should be retained for a longer period, however, if required by [CONTACT_427].  It is 
the responsibility of the sponsor to notify the UAB Central Unit, which will notify the 
investigators, when these documents no longer need to be retained.  
15.6.  Protocol Deviations  
Each investigator must adhere to the protocol as detailed in this document and agree that any 
changes to the protocol must be approved by [CONTACT_114825] #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
59 
 seeking approval from the IRB/IEC.  Each investigator will be responsible for enrolling only 
those study participants who have met protocol eligibility cr iteria. 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual of 
Procedures requirements.  The noncompliance may be either on the part of the study 
participant, the investigator, or the study site staff.  As a result of deviations, corrective actions 
are to be developed by [CONTACT_3483].  
These practices are consistent with GCP:  
4.[ADDRESS_128322] be sent 
to the local IRB per the IRB’s guidelines. 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
60 
 16. PUBLICATION POLICY  
Following completion of this study, the investigators are expected to publish the results in a 
scientific journal.  All research reports and other publications resulting from the work completed 
in this protocol shall:  
• Acknowledge the support of the National Institutes of Health whenever publicizing the results from this clinical trial in any media by [CONTACT_114826]:  
o Be submitted to the Project Director in the form of advance copi[INVESTIGATOR_114745].  
o Be furnished in a list of publications resulting from the research as part of the annual progres s report submitted to the principal investigator. 
 
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted 
a trials -registration policy as a condition for publication.  This policy requires that all clinical trials 
be registered in a public trials registry such as ClinicalTrials.gov , which is sponsored by [CONTACT_38082].  Other biomedical journals are considering adopting similar policies.  
Unless exempted, this trial will be registered prior to enrollment of study subjects.  It  is the 
responsibility of the study’s  PI (e.g., [CONTACT_114845]) to register the non-exempted trial s and post 
results in compliance with Public Law 110-85, the Food and Drug Administration Amendments 
Act of 2007 (FDAAA).
 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128323] mental retardation caused by 
[CONTACT_114827]. Lancet . 1974;1:1- 5. 
2. Fowler KB, McCollister FP, Dahle AJ, et  al. Progressive and fluctuating sensorineural hearing 
loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr . 1997;130:624-
30. 
3. Harris S, Ahlfors K, Ivarsson S, et al. Congenital cytomegalovirus infection and sensorineural hearing loss. Ear & Hearing . 1984;5:352 -5. 
4. Fowler KB, Dahle AJ, Boppana SB, et al. Newborn hearing screening: will children with hearing 
loss caused by [CONTACT_114828]? J Pediatr . 1999;135:60- 4. 
5. Demmler GJ. Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis . 
1991;13:315 -29. 
6. Stagno S, Whitley RJ. Herpesvirus infections of pregnancy. Part I: Cytomegalovirus and Epstein -
Barr virus infections. N Engl J Med . 1985;313:1270- 4. 
7. McCracken GH, Jr., Shinefield HM, Cobb K, et al. Congenital cytomegalic inclusion disease. A 
longitudinal study of 20 patients. Am J Dis Child . 1969;117:522- 39. 
8. Pass RF, Stagno S, Myers GJ, et al. Outcome of symptomatic congenital cytomegalovirus 
infection: results of long- term longitudinal follow -up. Pediatrics . 1980;66:758- 62. 
9. Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N 
Engl J Med. 1 971;285:203 -14. 
10. Weller TH, Hanshaw JB. Virologic and clinical observations on cytomegalic inclusion disease. N 
Engl J Med. 1962;266:1233 -1244.  
11. Conboy TJ, Pass RF, Stagno S, et al. Early clinical manifestations and intellectual outcome in 
children w ith symptomatic congenital cytomegalovirus infection. J Pediatr . 1987;111:[ADDRESS_128324] SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol . 
2007.  
13. Dahle AJ, Fowler KB, Wright JD, et al. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. Journal of the American Academy of Audiology. 2000;11:283-
90. 
14. Yow MD, Demmler GJ. Congenital cytomegalovirus disease --20 years is long enough. N Engl J 
Med. 1992;326:702- 3. 
15. Arvin AM, Fast P, Myers M, et al. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis . 2004;39:233- 9. 
16. Boppana SB, Ross SA, Novak Z, et al. Dried blood spot real -time polymerase chain reaction 
assays to screen newborns for congenital cytomegalovirus infection. JAMA. 2010;303:1375- 82. 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 
62 
 17. Barbi M, Binda S, Caroppo S. Diagnosis of congenital CMV infection via dried blood spots. Rev 
Med Virol . 2006;16:385- 92. 
18. Walter S, Atkinson C, Sharland M, et al. Congenital cytomegalovirus: Association between dried 
blood spot viral load and hearing loss. Arch Dis Child Fetal Neonatal Ed. 2007;2007 Nov 26 
[Epub ahead of print]. 
19. Bradford RD, Cloud G, Lakeman AD, et al. Detection of cytomegalovirus (CMV) DNA by [CONTACT_114829]. J Infect Dis. 2005;191:[ADDRESS_128325] of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr . 2003;143:16- 25. 
21. Berg FS. Characteristics of the target population. In: Berg FS, Blair JC, Viehweg SH, Wilson-
Vlotman A, eds. Educational Audiology for the Hard of Hearing Child. Orlando: Grune and 
Stratton, 1986.  
22. Habilitation and rehabilitation. In: Northern JL, e d. Hearing Disorders . [LOCATION_011]: Little, Brown, and 
Company, 1976.  
23. Investigator's Brochure. Ro107- 9070 (Valcyte , Valganciclovir). 2002.  
24. Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus 
disease. J Infect Dis . 2008;197:836- 45. 
25. Trang JM, Kidd L, Gruber W, et al. Linear single -dose pharmacokinetics of ganciclovir in 
newborns with congenital cytomegalovirus infections. Clinical Ph armacology & Therapeutics . 
1993;53:15- 21. 
26. Stagno S, Reynolds DW, Tsiantos A, et al. Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections. J Infect 
Dis. 1975;132:568- 77. 
27. Boppana SB, Fowler KB, Pass RF, et al. Congenital cytomegalovirus infection: association 
between virus burden in infancy and hearing loss. J Pediatr . 2005;146:817 -823. 
28. Bauer PW, Parizi -Robinson M, Roland PS, et al. Cytomegalovirus in the per ilymphatic fluid. 
Laryngoscope. 2005;115:223-5.  
29. Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. J Infect Dis . 1997;175:1080- 6. 
30. Schwartz GJ, Brion LP, Spi[INVESTIGATOR_626] A. The use of plasma creatinine concentration for estimating 
glomerular filtration rate in infants, children, and adolescents. Pediatric Clinics of North America. 
1987;34:571 -590. 
31. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with 
CKD. J Am Soc Nephrol . 2009;20:629- 637. 
  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
 _____________________________________________________________________________________________  
63 SUPPLEMENTS/APPENDICES  
 
  
 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
64 APPENDIX A: SCHEDULE OF EVENTS  
 Enrollment 
(Window: Day -
90 to Day -1) Randomization  
(Window: Day -30 
to Day 1)  Study Day  Study Month  
1            
(day -3 to 
day 1)  14 
 (± 2 
days)  28 
 (± 2 
days)  42 
 (± 2 
days)  70 
 (± 4 
days)  4 
 (± 7 
days)  6 
(± 7 
days)  
Following study enrollment, testing of 
Guthrie card for CMV DNA by [CONTACT_954] (if 
congenital CMV infection has not already 
been documented during first month of life)  X  
       
Confirmation of congenital CMV infection 
by [CONTACT_114830] -positive Guthrie card   X 
      
Baseline demographicsa  X       
Hematology Safety Labsb   X X X X X   
Chemistry Safety Labsc   X X X X X   
Weight  and Length    X X X     
Adverse Event Assessment    X X X X X   
Concurrent Medications    X X X X X   
Updated results of any etiological 
investigations for SNHL    X X X X X X X 
Hearing Assessment   
Xd 
Day -90 to Day -1       X 
-14 to 
+30 
days  
Virology Specimens for CMV Viral Loade   X X X X X X X 
Ganciclovir Population Pharmacokineticsf    X X X    
Valganciclovir vs. Placebo Administrationg       
Total volume of blood required    2.0 mL 2.25 2.25 2.25 2.0 0.5 0.5 mL 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.[ADDRESS_128326] of date of birth; gender; race; ethnicity; birth weight; length at birth, if available; head circumference at birth, if 
available; and gestational age at birth.  Degree of CMV disease involvement consists of neuroimaging abnormalities if imaging was performed; petechiae at 
any time from birth through study randomization, if known; thrombocytopenia at any time from birth through study randomization, if obtained; hepatomegaly at 
any time from birth through study randomization, if note d; splenomegaly at any time from birth through study randomization, if noted; CSF white blood cell 
count at any time from birth through study randomization, if obtained; CSF protein concentration at any time from birth through study randomization, if obtai ned; CSF CMV PCR at any time from birth through study randomization, if performed; seizures at any time from birth through study randomization, if 
noted; elevated transaminases at any time from birth through study randomization, if obtained; elevated bilirubin at any time from birth through study randomization, if obtained; m edical history and baseline conditions prior to study randomization, by [CONTACT_6764], chorioretinitis, intrauterine growth restriction; 
urine CMV testing (e.g., viral culture, shell -vial culture, PCR) within 90 days prior to study enrollment, if obtained clinically  
b. WBC with differential, hemoglobin, Platelet enumeration (approximate total blood needed for these tests is 0.5 mL)  
c. ALT, total bilirubin, creatinine (approximate total blood nee ded for these tests is 1.0 mL)  
d. BSER and/or VRA (to assess neuro-otologic status) and OAEs will be obtained.  If the BSER and/or VRA is abnormal, then bone conduction will be obtained to distinguish between sensorineural hearing loss, conductive loss, and mixed loss.  If the OAEs are abnormal, then acoustic immittance measures 
(tympanometry and acoustic reflexes) will be obtained to better define the middle or inner ear abnormality (e.g., otitis medi a). 
e. Required amount of whole blood for quant itative CMV PCR  is at least 0.5 mL. Urine collection by [CONTACT_114831]. Saliva 
collection by [CONTACT_114832]–tipped swabs  for quantitative PCR.  
f. Required amount of whole blood for plasma ganciclovir determination is at least 0.25 mL  
g. Va lganciclovir or placebo administration begins on Day 1 of the study; study medication dose adjusted for weight change, if needed, at each study visit while 
on treatment  
 
 
 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
66 
  
CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
ESTIMATING SEVERITY GRADE  
Clinical adverse event 
NOT identified 
elsewhere in this 
DAIDS AE grading table  Symptoms causing no or minimal 
interference with 
usual social & functional activities
 Symptoms causing greater than minimal 
interference with usual 
social & functional 
activities
 Symptoms causing inability to perform usual 
social & functional 
activities
 Symptoms causing 
inability to perform basic 
self-care functions OR 
Medical or operative intervention indicated to 
prevent permanent 
impairment, persistent 
disability, or death  
SYSTEMIC  
Acute systemic 
allergic reaction  Localized urticaria 
(wheals) with no 
medical intervention indicated  Localized urticaria with 
medical intervention 
indicated OR Mild 
angioedema with no 
medical intervention indicated  Generalized urticaria 
OR Angioedema with 
medical intervention 
indicated OR 
Symptomatic mild bronchospasm  Acute anaphylaxis OR 
Life-threatening 
bronchospasm OR laryngeal edema 
Chills  Symptoms causing no 
or minimal 
interference with 
usual  social & 
functional activities  Symptoms causing greater than minimal 
interference with usual 
social & functional 
activities  Symptoms causing 
inability to perform usual 
social & functional activities  NA 
Fatigue  
Malaise  Symptoms causing no or minimal 
interference with 
usual social & functional activities  Symptoms causing greater than minimal 
interference with usual 
social & functional activities  Symptoms causing inability to perform usual 
social & functional 
activities  Incapacitating fatigue/ 
malaise sympt oms 
causing inability to perform basic self -care 
functions  
Fever (nonaxillary)  37.7 – 38.6°C 38.7 – 39.3°C 39.4 – 40.5°C > 40.5°C  APPENDIX B:  DIVISION OF AIDS TOXICITY TABLES 
 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
67 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
Pain (indicate body 
site) 
DO NOT use for pain 
due to injection (See 
Injection Site 
Reactions: Injection 
site pain)  
See also Headache, 
Arthralgia, and 
Myalgia  Pain causing no or 
minimal interference 
with usual social & functional activities  Pain causing greater 
than minimal 
interference with usual 
social & functional 
activities  Pain causing inability to 
perform usual social & 
functional activities  Disabling pain causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_059] (other than emergency room visit) indicated  
Unintentional weight loss NA 5 – 9% loss in body 
weight from baseline  10 – 19% loss in body 
weight from baseline  ≥ 20% loss in body 
weight from baseline OR  
Aggressive intervention 
indicated [e.g., tube 
feeding or total 
parenteral nutrition 
(TPN)] 
INFECTION  
Infection (any other than HIV infection)  Localized, no 
systemic antimicrobial 
treatment indicated 
AND Symptoms 
causing no or minimal 
interference with 
usual social & 
functional activities  Systemic antimicrobial treatment indicated 
OR Symptoms 
causing greater than 
minimal interference 
with usual social & functional activities  Systemic antimicrobial treatment indicated 
AND Symptoms causing inability to perform usual 
social & functional 
activities OR Operative 
intervention (other than simple incision and 
drainage) indicated  Life-threatening 
consequences (e.g., septic shock)  
INJECTION SITE REACTIONS  
Injection site pain 
(pain without touching)  
Or 
Tenderness (pain 
when area is touched)  Pain/tenderness causing no or minimal 
limitation of use of 
limb Pain/tenderness 
limiting use of limb OR 
Pain/tenderness 
causing greater than 
minimal interference 
with usual social & functional activities  
 Pain/tenderness causing inability to 
perform usual social & 
functional activities  
 Pain/tenderness causing 
inability to perform basic 
self-care function OR 
Hospi[INVESTIGATOR_059] (other than emergency room 
visit) indicated for 
mana gement of 
pain/tenderness  
Injection site reaction (localized)  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
68 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
 Adult > 15 years  
 Erythema OR 
Induration  
of 5x5 cm – 9x9 cm 
(or 25 cm2 – 81cm2) Erythema OR Induration OR  Edema  
> 9 cm any diameter  
(or > 81 cm
2) Ulceration OR Secondary infection OR 
Phlebit is OR Sterile 
abscess OR Drainage  Necrosis (involving 
dermis and deeper 
tissue)  
 
 Pediatric ≤ 15 
years  Erythema OR 
Induration OR Edema 
present but ≤ 2.5 cm 
diameter  Erythema OR 
Induration OR Edema 
> 2.5 cm diameter but 
< 50% surface area of 
the extremity segment 
(e.g., upper arm/thigh)  Erythema OR Induration 
OR Edema involving  
≥ 50% surface area of 
the extremity segment 
(e.g., upper arm/thigh) 
OR Ulceration OR 
Secondary infection OR 
Phlebitis OR Sterile abscess OR Drainage  Necrosis (involving dermis and deeper tissue)  
Pruritis associated with injection  
See also Skin: Pruritis 
(itching - no skin 
lesions)  Itching localized to injection site AND 
Relieved 
spontaneously or with 
< 48 hours treatment  Itching beyond the 
injection site but not 
generalized OR Itc hing 
localized to injection 
site requiring ≥  48 
hours treatment  Generalized itching 
causing inability to 
perform usual social & functional activities  NA 
SKIN – DERMATOLOGICAL  
Alopecia  Thinning detectable 
by [CONTACT_111186] 
(or by [CONTACT_111187])  Thinning or patchy hair 
loss detectable by 
[CONTACT_114833] – rash Localized macular rash  Diffuse macular, 
maculopapular, or 
morbilliform rash OR 
Target lesions  Diffuse macular, 
maculopapular, or 
morbilliform rash with 
vesicles or limited 
number of bullae OR 
Superficial ulcerations 
of mucous membrane 
limited to one site Extensive or generalized bullous lesions OR 
Stevens -Johnson 
syndrome OR Ulceration of mucous membrane 
involving two or more 
distinct mucosal sites OR Toxic epi[INVESTIGATOR_7387] (TEN) 
Hyperpi[INVESTIGATOR_114746] #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
69 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
Pruritis (itching – no 
skin lesions)  
(See also Inj ection 
Site Reactions: 
Pruritis associated with injection)  Itching causing no or 
minimal interference 
with usual social & functional activities  Itching causing greater 
than minimal 
interference with usual 
social & functional 
activities  Itching causing inab ility 
to perform usual social & functional activities  NA 
 
CARDIOVASCULAR  
Cardiac arrhythmia (general)  
(By [CONTACT_10871])  Asymptomatic AND 
No intervention indicated  Asymptomatic AND Non- urgent medical 
intervention indicated  Symptomatic, non- life-
threatening AND Non-
urgent medical 
intervention indicated  Life-threatening 
arrhythmia OR Urgent intervention indicated  
Cardiac -
ischemia/infarction  NA NA Symptomatic ischemia (stable angina) OR 
Testing consistent with 
ischemia  Unstable angina OR 
Acute myo cardial 
infarction  
Hemorrhage (significant acute blood loss)  NA Symptomatic AND No 
transfusion indicated  Symptomatic AND 
Transfusion of ≤  2 units 
packed RBCs (for 
children ≤ 10 cc/kg) 
indicated  Life-threatening 
hypotension OR 
Transfusion of > 2 units packed RBCs (for 
children > 10 cc/kg) 
indicated  
Hypertension  
 Adult > 17 years  
(with repeat 
testing at same 
visit) 
 > 140 – 159 mmHg 
systolic 
OR 
> 90 – 99 mmHg 
diastolic  > 160 – 179 mmHg 
systolic OR 
> 100 – 109 mmHg 
diastolic  
 > 180 mmHg systolic  
OR 
> 110 mmHg diastolic  
 Life-threatening 
consequences (e.g., 
malignant hypertension) 
OR Hospi[INVESTIGATOR_373] (other than 
emergency room visit) 
 Pediatric ≤ 17 
years  
(with repeat 
testing at same visit) 
 NA 91
st –  94th percentile 
adjusted for age, 
length, and gender (systolic and/or 
diastolic)  ≥ 95
th percentile 
adjusted for age, length, 
and gender (systolic 
and/or diastolic)  Life-threatening consequences (e.g., 
malignant hypertension) OR Hospi[INVESTIGATOR_373] (other than emergency room visit) 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
70 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
Hypotension  NA Symptomatic, 
corrected with oral 
fluid replacement  Symptomatic, IV fluids 
indicated  Shock requiring use of 
vasopressors or 
mechanical assistance 
to maintain blood 
pressure  
 
Pericardial effusion  Asymptomatic, small 
effusion requiring no 
intervention  
 Asymptomatic, 
moderate or larger 
effusion requiring no intervention  
 Effusion with non-life 
threatening physiologic 
consequences OR 
Effusion with non-urgent 
intervention indicated  Life-threatening 
consequences (e.g., 
tamponade) OR Urgent intervention indicated  
Prolonged PR interval  
 Adult > 16 years  PR interval  0.21 – 0.25 sec  PR interval  
> 0.25 sec  Type II 2
nd degree AV 
block OR Ventricular 
pause > 3.0 sec  Complete AV block  
 Pediatric ≤ [ADDRESS_128327] degree AV block  
(PR > normal for age 
and rate)  Type I 2nd degree AV 
block  Type II 2nd degree AV 
block  Complete AV block  
Prolonged QTc  
 Adult > 16 years  
 Asymptomatic, QTc 
interval 0.45 – 0.47 
sec OR Increase interval < 0.03 sec 
above baseline  Asymptomatic, QTc 
interval 0.48 – 0.49 
sec OR Increase in interv al 0.03 – 0.05 
sec above baseline  Asymptomatic, QTc 
interval ≥ 0.50 sec OR 
Increase in interval  ≥ 0.06 sec above 
baseline  Life-threatening 
consequences, e.g. 
Torsade de pointes or 
other associated serious 
ventricular dysrhythmia  
 Pediatric ≤ 16 years  Asymptomatic, QTc 
interval 0.450 –  0.464 sec  Asymptomatic, QTc interval 0.465 –  0.479 sec  Asymptomatic, QTc 
interval ≥ 0.480 sec  Life-threatening 
consequences, e.g.  
Torsade de pointes  or 
other associated serious ventricular dysr hythmia  
Thrombosis/embolism  NA Deep vein thrombosis 
AND No intervention 
indicated (e.g., 
anticoagulation, lysis 
filter, invasive procedure)  Deep vein thrombosis 
AND Intervention 
indicated (e.g., 
anticoagulation, lysis 
filter, invasive procedure)  Embolic  event (e.g., 
pulmonary embolism, life-threatening 
thrombus)  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
71 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
Vasovagal epi[INVESTIGATOR_1865] 
(associated with a 
procedure of any kind)  Present without loss 
of consciousness  Present with transient loss of consciousness  NA  NA 
Ventricular dysfunction 
(congestive heart  
failure)  NA Asymptomatic 
diagnostic finding AND intervention indicated  New onset with symptoms OR 
Worsening symptomatic 
congestive heart failure  Life-threatening congestive heart failure  
GASTROINTESTINAL  
Anorexia  Loss of appetite 
without decreased 
oral intake  
 Loss of appetite 
associated with 
decreased oral intake 
without significant 
weight loss  
 Loss of appetite 
associated with 
significant weight loss  Life-threatening 
consequences OR 
Aggressive intervention 
indicated [e.g., tube 
feeding or total 
parenteral nutrition 
(TPN)] 
Ascites Asymptomatic Symptomatic AND 
Intervention indicated 
(e.g., diuretics or 
therapeutic paracentesis)  Symptomatic despi[INVESTIGATOR_7389]-threatening consequences  
Cholecystitis  NA Symptomatic AND 
Medical intervention 
indicated 
 Radiologic, endoscopic, 
or operative intervention 
indicated  Life-threatening 
consequences (e.g., 
sepsis or perforation)  
Constipation  NA Persistent constipation 
requiring regular use 
of dietary 
modifications, 
laxatives, or enemas  Obstipation with manual 
evacuation indicated  Life-threatening 
consequences (e.g., 
obstruction)  
Diarrhea  
 Adult and 
Pediatric ≥ 1 year  Transient or 
intermittent epi[INVESTIGATOR_111084] ≤ 3 
stools over baseline per 24- hour period  Persistent epi[INVESTIGATOR_114747] 
4 – 6 stools over 
baseline per 24-hour 
period  Bloody diarrhea OR 
Increase of ≥ 7 stools 
per 24- hour period OR 
IV fluid replacement 
indicated  Life-threatening 
consequences (e.g., 
hypotensive shock)  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
72 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
 Pediatric < 1 year  Liquid stools (more 
unformed than usual) 
but usual number of stools  Liquid stools with 
increased number of 
stools OR Mild dehydration  Liquid stools with moderate dehydration  Liquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR 
Hypotensive shock  
Dysphagia-
Odynophagia  Symptomatic but able to eat usual diet  Symptoms causing 
altered dietary intake 
without medical 
intervention indicated  Symptoms causing 
severely altered dietary 
intake with medical 
intervention indicated  Life-th reatening 
reduction in oral intake  
Mucositis/stomatitis  (clinical exam ) 
Indicate site (e.g., larynx, oral)  
See Genitourinary for Vulvovaginitis  
See also Dysphagia-
Odynophagia and Proctitis Erythema of the 
mucosa Patchy 
pseudomembranes or ulcerations  Confluent 
pseudomembranes or ulcerations OR Mucosal bleeding with minor trauma  Tissue necrosis OR Diffuse spontaneous mucosal bleeding OR Life-threatening consequences (e.g., aspi[INVESTIGATOR_1516], choking)  
Nausea  Transient (< 24 hours) 
or intermittent nausea 
with no or minimal 
interference with oral 
intake  Persistent nausea 
resulting in decreased 
oral intake for 24 – 48 
hours  Persistent nausea 
resulting in minimal oral 
intake for > 48 hours 
OR Aggressive 
rehydration indicated (e.g., IV fluids)  Life-threatening 
consequences (e.g., 
hypotensive shock)  
Pancreatitis  NA Symptomatic AND 
Hospi[INVESTIGATOR_7392] (other than emergency room visit) Symptomatic AND 
Hospi[INVESTIGATOR_374] 
(other than emergency room visit)  Life-threatening 
consequences (e.g., 
circulatory f ailure, 
hemorrhage, sepsis)  
Proctitis (functional - 
symptomatic) 
Also see Mucositis/stomatitis  for clinical exam  
 
 Rectal discomfort 
AND No intervention indicated  
 Symptoms causing greater than minimal 
interference with usual 
social & functional 
activities OR Medical 
intervention indicated  Symptoms causing 
inability to perform usual 
social & functional 
activities OR Operative intervention indicated  Life-threatening consequences (e.g., perforation)  
 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
73 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
Vomiting  Transient or 
intermittent vomiting 
with no or minimal 
interference with oral 
intake  Frequent epi[INVESTIGATOR_114748] (e.g., IV fluids)  Life-threatening 
consequences (e.g., 
hypotensive shock) 
NEUROLOGIC  
Alteration in 
personality -behavior 
or in mood (e.g., agitation, anxiety, 
depression, mania, psychosis) Alteration causing no 
or minimal interference with usual social & functional activities  Alteration causing greater than minimal interference with usual social & functional activities  Alteration causing inability to perform usual social & functional activities  Behavior potentially harmful to self or others (e.g., suicidal and homicidal ideation or attempt, acute psychosis) OR Causing inability to perform basic 
self-care functions  
Altered Mental Status  
For Dementia, see 
Cognitive and 
behavioral/attentional 
disturbance (including 
dementia and 
attention deficit 
disorder)  Changes causing no 
or minimal 
interference with 
usual social & functional activities  Mild lethargy or somnolence causing 
greater than minimal 
interference with usual 
social & functional 
activities  Confusion, memory 
impairment, lethargy, or 
somnolence causing 
inability to perform usual 
social & functional 
activities  Delirium OR obtundation, OR coma  
Ataxia  Asymptomatic ataxia 
detectable on exam 
OR Minimal ataxia 
causing no or minimal 
interference with 
usual social & functional activities  Symptomatic ataxia causing greater than 
minimal interference 
with usual social & functional activities  Symptomatic ataxia causing inability to 
perform usual social & 
functional activities  Disabling ataxia causing 
inability to perform basic self-care functions  
Cognitive and 
behavioral/attentional 
disturbance (including 
dementia and 
attention deficit disorder)  Disability causing no 
or minimal 
interference with 
usual social & 
functional activities 
OR Specialized 
resources not indicated  Disability causing 
greater than minimal 
interference with usual 
social & functional 
activities OR 
Special ized resources 
on part -time basis 
indicated  Disability causing inability to perform usual 
social & functional 
activities OR 
Specialized resources 
on a full -time basis 
indicated  Disability causing inability to perform basic 
self-care functions OR 
Institutio nalization 
indicated  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
74 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
CNS ischemia  
(acute)  NA NA Transient ischemic 
attack  Cerebral vascular 
accident (CVA, stroke) 
with neurological deficit  
Developmental delay 
– Pediatric ≤ 16 
years  Mild developmental 
delay, either motor or 
cognitive, as 
determined by  
[CONTACT_7425] a developmental 
screening tool 
appropriate for the setting  Moderate developmental delay,  
either motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting  Severe developmental 
delay, either motor or 
cognitive, as determined by [CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting  Developmental 
regression, either motor 
or cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the setting  
Headache  Symptoms causing no or minimal 
interference with 
usual social & functional activities  Symptoms causing greater than minimal 
interference with usual 
social & functional activities  Symptoms causing inability to perform usual 
social & func tional 
activities  Symptoms causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_374] (other than emergency 
room visit) OR 
Headache with 
significant impairment of 
alertness or other 
neurologic function  
Insomnia  NA Difficulty sleepi[INVESTIGATOR_114749] & functional activities  Difficulty sleepi[INVESTIGATOR_114750] & 
functional activities  Disabling insomnia 
causing inability to 
perform basic self -care 
functions  
Neuromuscular 
weakness  
(including myopathy & 
neuropathy)  Asymptomatic with 
decreased strength 
on exam OR Minimal 
muscle weakness 
causing no or minimal 
interference with 
usual social & 
functional activities  Muscle weakness 
causing greater than 
minimal interference 
with usual social & functional activities  Muscle weakness causing inability to 
perform usual social & 
functional activities  Disabling muscle 
weakness causing 
inability to perform basic 
self-care functions OR 
Respi[INVESTIGATOR_114751] #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
75 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
Neurosensory 
alteration (including 
paresthesia and painful neuropathy)  Asymptomatic with 
sensory alteration on exam or minimal paresthesia causing no or minimal interference with 
usual social & 
functional activities  Sensory alteration or paresthes ia causing 
greater than minimal interference with usual social & functional activities  Sensory alteration or paresthesia causing inability to perform usual social & functional activities  Disabling sensory alteration or paresthesia causing inability to perform basic self -care 
functions  
 
Seizure: ( new onset )  
– Adult ≥ 18 years  
See also Seizure: 
(known pre-existing seizure disorder)  NA 1 seizure  2 – 4 seizures  Seizures of any kind which are prolonged, 
repetitive (e.g., status 
epi[INVESTIGATOR_7397]), or difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
Seizure: ( known pre-
existing seizure 
disorder )  
– Adult ≥ 18 years  
For worsening of 
existing epi[INVESTIGATOR_114752].  NA Increased frequency of pre-existing seizures 
(non-repetitive) without 
change in seizure 
character OR 
Infrequent break -
through seizures while on stable medication 
in a previously 
controlled seizure disorder  Change in seizure character from baseline 
either in duration or 
quality (e.g., severity or  focality)  Seizures of any k ind 
which are prolonged, 
repetitive (e.g., status 
epi[INVESTIGATOR_7397]), or difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
Seizure  
– Pediatric < 18 
years  Seizure, generalized 
onset with or without secondary 
generalization, lasting 
< 5 minutes with < [ADDRESS_128328] ictal state  Seizure, generalized 
onset with or without secondary 
generalization, lasting 
5 – 20 minutes with  
< [ADDRESS_128329] ictal 
state  Seizure, generalized 
onset with or without secondary 
generalization, lasting  > 20 minutes  Seizure, generalized 
onset with or without secondary 
generalization, requiring intubation and sedation  
Syncope (not 
associated with a 
procedure)  NA Present  NA NA 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
76 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
Vertigo  Vertigo causing no or 
minimal interference 
with usual social & functional activities  Vertigo causing 
greater than minimal 
interference with usual 
social & functional 
activities  Vertigo causing inability 
to perform usual social 
& functional activities  Disabling vertigo 
causing inability to 
perform basic self -care 
functions  
RESPI[INVESTIGATOR_114753] (acute)  FEV1 or peak flow 
reduced to  
70 – 80% FEV1 or peak flow  
50 – 69% FEV1 or peak flow  
25 – 49%  Cyanosis OR FEV1 or 
peak flow < 25% OR 
Intubation  
Dyspnea or respi[INVESTIGATOR_114754] ≥ 14 years  Dyspnea on exertion 
with no or minimal 
interference with 
usual social & 
functional activities  Dyspnea on exertion 
causing greater than minimal interference 
with usual social & 
functional activities  Dyspnea at rest causing inability to perform usual social & functional 
activities  Respi[INVESTIGATOR_114755] < 14 
years  Wheezing OR 
minimal increase in 
respi[INVESTIGATOR_114756] 90 
– 95% Dyspnea at rest causing inability to perform usual 
social & functional 
activities OR Pulse oximetry < 90%  Respi[INVESTIGATOR_114757] & 
functional activities  Joint pain causing greater than minimal 
interference with usual 
social & functional 
activities  Joint pain causing 
inability to perform usual 
social & functional activities  Disabling joint pain 
causing inability to 
perform basic self -care 
functions  
Arthritis 
See also Arthralgia  Stiffness or joint 
swelling causing no or 
minimal interference 
with usual social & functional activities  Stiffness or joint swelling causing 
greater than minimal 
interference with usual 
social & functi onal 
activities  Stiffness or joint 
swelling causing 
inability to perform usual 
social & functional activities  Disabling joint stiffness or swelling causing 
inability to perform basic 
self-care functions  
Bone Mineral Loss  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
77 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
 Adult ≥ 21 years  BMD t -score  
-2.5 to -1.0  BMD t -score < -2.5 Pathological fracture 
(including loss of 
vertebral length)  Pathologic fracture 
causing life-threatening 
consequences  
 Pediatric < 21 
years  BMD z-score  -2.5 to -1.0 BMD z-score < -2.5 Pathological fracture 
(including loss of 
vertebral length)  Pathologic fracture causing life-threatening 
consequences  
Myalgia  
(non-injection site) Muscle pain causing 
no or minimal 
interference with 
usual social & functional activities  Muscle pain causing greater than minimal 
interference with usual 
social & functional activities  Muscle pain causing inability to perform usual 
social & functional 
activities  Disabling muscle pain 
causing inability to 
perform basic self -care 
functions  
Osteonecrosis  NA Asymptomatic with radiographic findings 
AND No operative 
intervention indicated  Symptomatic bone pain 
with radiographic 
findings OR Operative intervention indicated  Disabling bone pain with 
radiographic findings 
causing inability to 
perform basic self -care 
functions  
GENITOURINARY  
Cervicitis  
(symp toms ) 
(For use in studies evaluating topi[INVESTIGATOR_114758])  
For other cervicitis see 
Infection: Infection 
(any other than HIV 
infection)  Symptoms causing no 
or minimal 
interference with 
usual social & 
functional activities  Symptoms causing 
greater than minimal 
interference with usual 
social & functional activities  Symptoms causing inability to perform usual 
social & functional 
activities  
 Symptoms causing inability to perform basic 
self-care functions  
Cervicitis  
(clinical exam ) 
(For use in studies 
evaluating topi[INVESTIGATOR_114758])  
For other cervicitis see 
Infection: Infection 
(any other than HIV 
infection)  Minimal cervical 
abnormalities on 
examination (erythema, 
mucopurulent 
discharge, or friability) 
OR Epi[INVESTIGATOR_111098]  
< 25% of total surface  Moderate cervical 
abnormalities on examination (erythema, mucopurulent discharge, or friability) OR Epi[INVESTIGATOR_111099] 25 – 49% 
total surface  Severe cervical 
abnormalities on examination (erythema, mucopurulent discharge, or friability) OR Epi[INVESTIGATOR_111100]  
50 – 75% total surface  Epi[INVESTIGATOR_111100]  
> 75% total surface  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
78 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
Inter-menstrual 
bleeding (IMB)  Spotting observed by [CONTACT_114834]-menstrual 
bleeding not greater in duration or amount than usual menstrual cycle Inter-menstrual bleeding 
greater in duration or amount than usual menstrual cycle  Hemorrhage with life-threatening hypotension OR Operative intervention indicated  
Urinary tract 
obstruction (e.g., stone)  NA Signs  or symptoms of 
urinary tract 
obstruction without  hydronephrosis or renal dysfunction  Signs or symptoms of urinary tract obstruction with hydronephrosis or renal dysfunction  Obstruction causing life-threatening consequences  
Vulvovaginitis  
(symptoms) 
(Use in studies 
evaluating topi[INVESTIGATOR_111097])  
For other 
vulvovaginitis see 
Infection: Infection 
(any other than HIV infection)
 Symptoms causing no or minimal 
interference with usual social & 
functional activities  Symptoms causing 
greater than minimal interference with usual 
social & functional activities  Symptoms causing inability to perform usual social & functional activities  
 Symptoms causing inability to perform basic self-care functions  
Vulvovaginitis  
(clinical exam ) 
(Use in studies 
evaluating t opi[INVESTIGATOR_111097])  
For other 
vulvovaginitis see 
Infection: Infection 
(any other than HIV infection)  Minimal vaginal 
abnormalities on examination OR Epi[INVESTIGATOR_111100]  
< 25% of total surface  Moderate vaginal abnormalities on examination OR Epi[INVESTIGATOR_111101] 
25 - 49% total surface  Severe vaginal abnormalities on examination OR Epi[INVESTIGATOR_111100]  
50 - 75% total surface  Vaginal perforation OR Epi[INVESTIGATOR_111100]  
> 75% total surface  
OCULAR/VISUAL  
Uveitis  Asymptomatic but 
detectable on exam  Symptomatic anterior 
uveitis OR Medical intervention indicated  Posterior or pan -uveitis 
OR Operative intervention indicated  Disabling visual loss in 
affected eye(s)  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
79 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
Visual changes (from 
baseline)  Visual changes 
causing no or minimal 
interference with 
usual social & 
functional activities  Visual changes 
causing greater than 
minimal interference 
with usual social & 
functional activities  Visual changes causing 
inability to perform usual 
social & functional activities  Disabling visual loss in affected eye(s)  
ENDOCRINE/METABOLIC  
Abnormal fat 
accumulation  
(e.g., back of neck, 
breasts, abdomen)  Detectable by [CONTACT_8712] (or by 
[CONTACT_111190])  Detectable on physical 
exam by [CONTACT_114835][INVESTIGATOR_114759]-threatening consequences (e.g., 
ketoacidosis, 
hyperosmolar non-ketotic coma)  
Gynecomastia  Detectable by [CONTACT_114836] (for young 
children and disabled adults)  Detectable on physical exam by [CONTACT_114837] & functional 
activities OR Thyroid 
suppression therapy 
indicated  Symptoms causing 
inability to perform usual 
social & functional 
activities OR 
Uncontrolled despi[INVESTIGATOR_114759]-threatening 
consequences (e.g., 
thyroid storm)  
Hypothyroidism  Asymptomatic Symptomatic causing 
greater than minimal 
interference with usual 
social & functional 
activities OR Thyroid 
replacement therapy 
indicated  Symptoms causing inability to perform usual 
social & functional 
activities OR 
Uncontrolled despi[INVESTIGATOR_114760]-threatening 
consequences (e.g., myxedema coma)  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
80 
 CLINICAL  
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIA LLY 
LIFE -THREATENING  
Lipoatrophy  
(e.g., fat loss from the 
face, extremities, buttocks)  Detectable by [CONTACT_8712] (or by 
[CONTACT_111190])  Detectable on physical 
exam by [CONTACT_114838] #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-[ADDRESS_128330] International Units are listed in italics  
Absolute CD4+ count  
– Adult and Pediatric  
> 13 years  
(HIV NEGATIVE ONLY ) 300 – 400/mm3 
300 – 400/µL  200 –  299/mm3 
200 – 299/µL  100 – 199/mm3 
100 – 199/µL  < 100/mm3 
< 100/µL  
Absolute lymphocyte 
count  
– Adult and Pediatric   
> 13 years  
(HIV NEGATIVE ONLY ) 600 – 650/mm3 
0.600 x 109 – 
0.650 x 109/L 500 – 599/mm3 
0.500 x 109 –  
0.599 x 109/L 350 – 499/mm3 
0.350 x 109 –   
0.499 x 109/L < 350/mm3 
< 0.350 x 109/L 
Absolute neutrophil count  (ANC)  
 Adult and Pediatric,  
> 7 days 1,000 – 1,300/mm3 
1.000 x 109 – 
1.300 x 109/L 750 – 999/mm3 
0.750  x 109 –  
0.999 x 109/L 500 – 749/mm3 
0.500  x 109 –  
0.749 x 109/L   < 500/m m3 
< 0.500 x 109/L 
 Infant∗†, 2 – ≤ 7 days  1,250 – 1,500/mm3 
1.250  x 109 –  
1.500 x 109/L 1,000 – 1,249/mm3 
1.000 x 109 –  
1.249 x 109/L 750 – 999/mm3 
0.750  x 109 –  
0.999  x 109/L < 750/mm3 
< 0.750 x 109/L 
 Infant∗†, 1 day 4,000 – 5,000/mm3 
4.000 x 109 –  
5.000 x 109/L 3,000 – 3,999/mm3 
3.000 x 109 –  
3.999 x109/L 1,500 – 2,999/mm3 
1.500 x 109 –  
2.999 x 109/L < 1,500/mm3 
< 1.500 x 109/L 
Fibrinogen, decreased  100 – 200 mg/dL  
1.00 – 2.00 g/L  
OR 
0.75 – 0.[ADDRESS_128331]  75 – 99 mg/dL  
0.75 – 0.99 g/L  
OR 
0.50 – 0.[ADDRESS_128332]  50 – 74 mg/dL  
0.50 – 0.74 g/L  
OR 
0.25 – 0.[ADDRESS_128333]  < 50 mg/dL  
< 0.50 g/L 
OR 
< 0.[ADDRESS_128334]  
OR  
Associated with gross 
bleeding  
Hemoglobin (Hgb)  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
82 
  LABORATORY 
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIALLY  
LIFE -THREATENING  
 Adult and Pediatric  
≥ 57 days  
(HIV POSITIVE  
ONLY ) 8.5 – 10.0 g/dL  
1.32 – 1.55 mmol/L  7.5 – 8.4 g/dL 
1.16 – 1.31 mmol/L  6.50 – 7.4 g/dL  
1.01 – 1.15 mmol/L  < 6.5 g/dL 
< 1.01 mmol/L  
 Adult and Pediatric  
≥ 57 days  
(HIV NEGATIVE 
ONLY )  10.0 – 10.9 g/dL 
1.55 – 1.69 mmol/L  
OR 
Any decrease  
2.5 – 3.4 g/dL  
0.39 – 0.53 mmol/L  9.0 – 9.9 g/dL  
1.40 – 1.54 mmol/L  
OR 
Any decrease  
3.5 – 4.4 g/dL  
0.54 – 0.68 mmol/L  7.0 – 8.9 g/dL  
1.09 – 1.39 mmol/L  
OR 
Any decrease  
≥ 4.5 g/dL  
≥ 0.69 mmol/L  < 7.0 g/dL 
< 1.09 mmol/L  
 
 Infant∗†, 36 – 56 days  
(HIV POSITIVE  OR 
NEGATIVE)  8.5 – 9.4 g/dL  
1.32 – 1.46 mmol/L  7.0 –  8.4 g/dL  
1.09 – 1.31 mmol/L  6.0 – 6.9 g/dL  
0.93 – 1.08 mmol/L  < 6.00 g/dL  
< 0.93 mmol/L  
 Infant∗†, 22 – 35 days  
(HIV POSITIVE  OR 
NEGATIVE)  9.5 – 10.5 g/dL  
1.47 – 1.63 mmol/L  8.0 – 9.4 g/dL  
1.24 – 1.46 mmol/L  7.0 – 7.9 g/dL  
1.09 – 1.23 mmol/L  < 7.00 g/dL  
< 1.09 mmol/L  
 Infant∗†, 1 – 21 days  
(HIV POSITIVE  OR 
NEGATIVE)  12.0 – 13.0 g/dL 
1.86 – 2.02 mmol/L  10.0 – 11.9 g/dL 
1.55 – 1.85 mmol/L  9.0 – 9.9 g/dL  
1.40 – 1.54 mmol/L  < 9.0 g/dL < 1.40 mmol/L  
International Normalized 
Ratio of prothrombin time (INR)  1.1 – 1.[ADDRESS_128335] 1.6 – 2.[ADDRESS_128336]  2.1 – 3.[ADDRESS_128337]  > 3.[ADDRESS_128338]  
Methemoglobin 5.0 – 10.0%  10.1 – 15.0%  15.1 – 20.0%  > 20.0%  
Prothrombin Time (PT) 1.1 – 1.[ADDRESS_128339]  1.26 – 1.[ADDRESS_128340]  1.51 – 3.[ADDRESS_128341]  > 3.[ADDRESS_128342]  
Partial Thromboplastin Time (PTT)  1.1 – 1.[ADDRESS_128343]  1.67 – 2.[ADDRESS_128344]  2.34 – 3.[ADDRESS_128345]  > 3.[ADDRESS_128346]  
Platelets, decreased  100,000 –  
124,999/mm3 
100.000 x 109 – 
124.999 x 109/L 50,000 –  
99,999/mm3 
50.000 x 109 – 
99.999 x 109/L 25,000 –  
49,999/mm3 
25.000 x 109 – 
49.999 x 109/L < 25,000/mm3 
< 25.000 x 109/L 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
83 
  LABORATORY 
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIALLY  
LIFE -THREATENING  
WBC , decreased  2,000 – 2,500/mm3 
2.000 x 109 –  
2.500 x 109/L 1,500 – 1,999/mm3 
1.500 x 109 –  
1.999 x 109/L 1,000 – 1,499/mm3 
1.000 x 109 –  
1.499 x 109/L < 1,000/mm3 
< 1.000 x 109/L 
CHEMISTRIES  Standard International Units are listed in italics   
Acidosis  NA pH < normal, but ≥ 7.3 pH < 7.3 without life-
threatening consequences  pH < 7.3 with life-threatening consequences  
Albumin, serum, low  3.0 g/dL – < LLN  
30 g/L –  < LLN  2.0 – 2.9 g/dL  
20 – 29 g/L  < 2.0 g/dL 
< 20 g/L NA 
Alkaline Phosphatase  1.25 – 2.[ADDRESS_128347]† 2.6 – 5.[ADDRESS_128348]† 5.1 – 10.[ADDRESS_128349]† > 10.[ADDRESS_128350]† 
Alkalosis NA pH > normal, but ≤ 7.5 pH > 7.5 without life-
threatening 
consequences  pH > 7.5 with life-
threatening 
consequences  
ALT (SGPT)  1.25 – 2.[ADDRESS_128351]  2.6 – 5.[ADDRESS_128352]  5.1 – 10.[ADDRESS_128353]  > 10.[ADDRESS_128354] (SGOT)  1.25 – 2.[ADDRESS_128355]  2.6 – 5.[ADDRESS_128356]  5.1 – 10.[ADDRESS_128357]  > 10.[ADDRESS_128358]  
Bicarbonate, serum, low  16.0 mEq/L – < LLN  
16.0 mmol/L –  < LLN  11.0 – 15.9 mEq/L  
11.0 – 15.9 mmol/L  8.0 – 10.9 mEq/L 
8.0 – 10.9 mmol/L  < 8.0 mEq/L < 8.0 mmol/L 
Bilirubin (Total)  
 Adult and Pediatric > 14 days  1.1 – 1.[ADDRESS_128359]  1.6 – 2.[ADDRESS_128360]  2.6 – 5.[ADDRESS_128361]  > 5.[ADDRESS_128362]  
 Infant∗†, ≤ 14 days  
(non- hemolytic)  NA 20.0 – 25.0 mg/dL  
342 – 428 µmol/L 25.1 – 30.0 mg/dL  
429 – 513 µmol/L > 30.0 mg/dL  
> 513.0 µmol/L 
 Infant∗†, ≤ 14 days  
(hemolytic) NA NA 20.0 – 25.0 mg/dL  
342 – 428 µmol/L > 25.0 mg/dL  
> 428 µmol/L  
Calcium, serum, high (corrected for albumin)  
 Adult and Pediatric  ≥ 7 days  10.6  – 11.5 mg/dL  
2.65 – 2.88 mmol/L  11.6  – 12.5 mg/dL  
2.89 – 3.13 mmol/L  12.6  – 13.5 mg/dL  
3.14 – 3.38 mmol/L  > 13.5 mg/dL  
> 3.38 mmol/L  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
84 
  LABORATORY 
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIALLY  
LIFE -THREATENING  
 Infant∗†, < 7 days  11.5 – 12.4 mg/dL  
2.88 – 3.10 mmol/L  12.5 – 12.9 mg/dL  
3.11 – 3.23 mmol/L  13.0 – 13.5 mg/dL  
3.245 – 3.38 mmol/L  > 13.5 mg/dL  
> 3.38 mmol/L  
Calcium, serum, low (corrected for albumin)  
 Adult and Pediatric  
≥ 7 days  7.8  – 8.4 mg/dL 
1.95 – 2.10 mmol/L  7.0  – 7.7 mg/dL 
1.75 – 1.94 mmol/L  6.1  – 6.9 mg/dL 
1.53 – 1.74 mmol/L  < 6.1 mg/dL < 1.53 mmol/L  
 Infant∗†, < 7 days  6.5 – 7.5 mg/dL 
1.63 – 1.88 mmol/L  6.0 – 6.4 mg/dL 
1.50 – 1.62 mmol/L  5.50 – 5.90 mg/dL  
1.38 – 1.51 mmol/L  < 5.50 mg/dL  
< 1.38 mmol/L  
Cardiac troponin I (cTnI)  NA NA NA Levels consistent with 
myocardial infarction 
or unstable angina as 
defined by [CONTACT_114839] T (cTnT) NA NA NA ≥ 0.20 ng/mL  
OR 
Levels co nsistent with 
myocardial infarction 
or unstable angina as 
defined by [CONTACT_114840] (fasting)  
 Adult ≥ 18 years  200 – 239 mg/dL  
5.18 – 6.19 mmol/L  240 – 300 mg/dL  
6.20 – 7.77 mmol/L  > 300 mg/dL  
> 7.77 mmol/L  NA 
 Pediatric < 18 years  170 – 199 mg/dL  
4.40 – 5.15 mmol/L  200 – 300 mg/dL  
5.16 – 7.77 mmol/L  > 300 mg/dL  
> 7.77 mmol/L  NA 
Creatine Kinase 3.0 – 5.[ADDRESS_128363]† 6.0 – 9.[ADDRESS_128364]† 10.0 – 19.[ADDRESS_128365]† ≥ 20.[ADDRESS_128366]† 
Creatinine  1.1 – 1.[ADDRESS_128367]† 1.4 – 1.[ADDRESS_128368]† 1.9 – 3.[ADDRESS_128369]† ≥ 3.[ADDRESS_128370]† 
Glucose, serum, high  
 Nonfasting  116 – 160 mg/dL  
6.44 – 8.88 mmol/L  161 – 250 mg/dL  
8.89 – 13.88 mmol/L  251 – 500 mg/dL  
13.89 – 27.75 mmol/L  > 500 mg/dL  
> 27.75 mmol/L 
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
85 
  LABORATORY 
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIALLY  
LIFE -THREATENING  
     Fasting  110 – 125 mg/dL  
6.11 – 6.94 mmol/L  126 – 250 mg/dL  
6.95 – 13.88 mmol/L  251 – 500 mg/dL  
13.89 – 27.75 mmol/L  > 500 mg/dL  
> 27.75 mmol/L 
 
Glucose, serum, low  
 Adult and Pediatric  
≥ 1 month  55 – 64 mg/dL  
3.05 – 3.55 mmol/L  40 – 54 mg/dL  
2.22 – 3.06 mmol/L  30 – 39 mg/dL  
1.67 – 2.23 mmol/L  < 30 mg/dL  
< 1.67 mmol/L  
 Infant∗†, < 1 month  50 – 54 mg/dL  
2.78 – 3.00 mmol/L  40 – 49 mg/dL  
2.22 – 2.77 mmol/L  30 – 39 mg/dL  
1.67 – 2.21 mmol/L  < 30 mg/dL  
< 1.67 mmol/L  
Lactate  < 2.[ADDRESS_128371] without acidosis  ≥ 2.[ADDRESS_128372] without 
acidosis  Increased lactate with 
pH < 7.3 without life-
threatening 
consequences  Increased lactate with 
pH < 7.3 with life-
threatening 
consequences  
LDL cholesterol (fasting)  
 Adult ≥ 18 years  130 – 159 mg/dL  
3.37 – 4.12 mmol/L  160 – 190 mg/dL  
4.13 – 4.90 mmol/L  ≥ 190 mg/dL  
≥ 4.91 mmol/L  NA 
 Pediatric > 2 - < 18 
years  110 – 129 mg/dL  
2.85 – 3.34 mmol/L  130 – 189 mg/dL  
3.35 – 4.90 mmol/L  ≥ 190 mg/dL  
≥ 4.91 mmol/L  NA 
Lipase  1.1 – 1.[ADDRESS_128373]  1.6 – 3.[ADDRESS_128374]  3.1 – 5.[ADDRESS_128375]  > 5.[ADDRESS_128376]  
Magnesium, serum, low  1.2  – 1.4 mEq/L 
0.60 – 0.70 mmol/L  0.9 – 1.1 mEq/L 
0.45 – 0.59 m mol/L  0.6 – 0.8 mEq/L 
0.30 – 0.44 mmol/L  < 0.60 mEq/L 
< 0.30 mmol/L  
Pancreatic amylase  1.1 – 1.[ADDRESS_128377]  1.6 – 2.[ADDRESS_128378]  2.1 – 5.[ADDRESS_128379]  > 5.[ADDRESS_128380]  
Phosphate, serum, low  
 Adult and Pediatric  
> 14 years  2.5 mg/dL – < LLN  
0.81 mmol/L –  < LLN  2.0 – 2.4 mg/ dL 
0.65 – 0.80 mmol/L  1.0 – 1.9 mg/dL 
0.32 – 0.64 mmol/L  < 1.00 mg/dL  
< 0.32 mmol/L  
 Pediatric 1 year – 14 
years  3.0 – 3.5 mg/dL 
0.97 – 1.13 mmol/L  2.5 – 2.9 mg/dL 
0.81 – 0.96 mmol/L  1.5 – 2.4 mg/dL 
0.48 – 0.80 mmol/L  < 1.50 mg/dL  
< 0.48 mmol/L  
 Pediatr ic < 1 year  3.5 – 4.5 mg/dL 
1.13 – 1.45 mmol/L  2.5 – 3.4 mg/dL 
0.81 – 1.12 mmol/L  1.5 – 2.4 mg/dL 
0.48 – 0.80 mmol/L  < 1.50 mg/dL  
< 0.48 mmol/L  
Collaborative Antiviral Study Group  DMID Protocol #11- 0069, Version 4.0  
CASG Valgan Toddler  28 April 2016  
 
Basic Self- care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 
Basic Self- care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks  and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, 
use of transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 
play activities, learning tasks, etc.). 
12-28-04   Version 1.0  
 
 _____________________________________________________________________________________________  
86 
  LABORATORY 
PARAMETER  GRADE 1  
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE GRADE 4  
POTENTIALLY  
LIFE -THREATENING  
Potassium, serum, high  5.6 – 6.0 mEq/L 
5.6 – 6.0 mmol/L 6.1 – 6.5 mEq/L 
6.1 – 6.5 mmol/L 6.6 – 7.0 mEq/L 
6.6 – 7.0 mmol/L > 7.0 mEq/L 
> 7.0 mmol/L 
Potassium, serum, low  3.0 – 3.4 mEq/L 
3.0 – 3.4 mmol/L 2.5 – 2.9 mEq/L 
2.5 – 2.9 mmol/L 2.0 – 2.4 mEq/L 
2.0 – 2.4 mmol/L < 2.0 mEq/L < 2.0 mmol/L 
Sodium, serum, high  146 – 150 mEq/L 
146 – 150 mmol/L  151 – 154 mEq/L 
151 – 154 mmol/L  155 – 159 mEq/L 
155 – 159 mmol/L  ≥ 160 mEq/L  
≥ 160 mmol/L  
Sodium, serum, low  130 – 135 mEq/L 
130 – 135 mmol/L  125 – 129 mEq/L 
125 – 129 mmol/L  121 – 124 mEq/L 
121 – 124 mmol/L  ≤ 120 mEq/L  
≤ 120 mmol/L  
Triglycerides (fasting)  NA 500 – 750 mg/dL  
5.65 – 8.48 mmol/L  751 – 1,200 mg/dL  
8.49 – 13.56 mmol/L  > 1,200 mg/dL  
> 13.56 mmol/L 
Uric acid  7.5 – 10.0 mg/dL  
0.45 – 0.59 mmol/L  10.1 – 12.0 mg/dL  
0.60 – 0.71 mmol/L  12.1 – 15.0 mg/dL  
0.72 – 0.89 mmol/L  > 15.0 mg/dL  
> 0.89 mmol/L  
URINALYSIS   Stand ard International Units are listed in italics  
Hematuria (microscopic)  6 – 10 RBC/HPF  > 10 RBC/HPF  Gross, with or without 
clots OR with RBC 
casts Transfusion indicated  
Proteinuria, random 
collection  1 + 2 – 3 + 4 + NA 
Proteinuria, 24 hour collection  
 Adult and Pediatric  
≥ 10 years  200 – 999 mg/24 h  
0.200 – 0.999 g/d  1,000 – 1,999 mg/24 h  
1.000 – 1.999 g/d  2,000 – 3,500 mg/24 h  
2.000 – 3.500 g/d  > 3,500 mg/24 h > 3.500 g/d  
 Pediatric > 3 mo -  
< 10 years  201 – 499 mg/ m2/24 h 
0.201 – 0.499 g/d  500 – 799 mg/m2/24 h 
0.500 – 0.799 g/d  800 – 1,000  
mg/m2/24 h 
0.800 – 1.000 g/d  > 1,000 mg/  m2/24 h 
> 1.000 g/d  
 
 
 